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Pancreatic cancer (PDAC) represents an extremely poor clinical outcome with a 5-year 
survival rate of <9%. It is anticipated to become the second leading cause of cancer-
related deaths in the industrialized countries by 2030. A vast majority of PDAC patients 
exhibit locally advanced or distant metastases at the time of diagnosis, which makes 
surgical resection challenging. The complex molecular heterogeneity within neoplastic-
epithelium and stromal cells profoundly attributes to this poor prognosis, and makes 
therapy challenging. Extensive whole genome sequencing and transcriptional profiling of 
PDAC biopsies identified the two most clinically relevant and molecularly distinct subtypes: 
the basal-like (BL) subtype displays highly aggressive phenotype, metastatic disease and 
chemoresistance profile in PDAC patients, whereas classical (CLA) subtype often 
responds to therapy and exhibits better prognosis. However, the coexisting stromal 
components (e.g. inflammatory macrophages and cancer-associated fibroblasts) within 
CLA or BL subtypes underlie distinct prognosis. Whether and how CLA or BL neoplastic 
cells shape the stromal microenvironment, and hence, determine PDAC aggressiveness 
and therapeutic vulnerabilities remain largely unresolved. Herein, we show that BL 
neoplastic cells recruit inflammatory macrophages, which foster highly inflamed and 
aggressive tumor phenotype in PDAC. We identified a mutually exclusive AP1-driven 
transcriptional program, which determines PDAC subtype identity and prognosis. CLA-
restricted JUNB/AP1 is associated with less aggressive and chemoresponsive CLA 
tumors; conversely, BL-restricted cJUN/AP1 largely controls tumor invasiveness, 
chemoresistance and proinflammatory program. Mechanistically, cJUN controls CCL2 
expression via enhancer-promoter regulation, which, in turn, facilitate recruitment of 
TNFα-producing macrophages in the PDAC microenvironment. Subsequently, TNFα 
switches PDAC subtype identity through converting CLA tumors into a highly aggressive 
BL phenotypic state by activating cJUN-CCL2 signaling axis, thus, forming a positive feed 
forward loop. Finally, we show that BRD4 regulates cJUN-transcription via enhancer-
promoter interactions; hence, pharmacological inhibition of the BRD4-cJUN axis induces 




provides compelling evidence that subtype-specific transcriptional program shapes the 
subtype identity, tumor aggressiveness and prognosis in PDAC. Thus, cJUNhigh/TNFαhigh 
subtype-specific precision therapy has the potential to overcome the highly aggressive 



















1.1 Pancreatic cancer 
Pancreatic cancer (PDAC) is a deadly disease, which has the highest mortality rate 
among solid tumors with a 5-year survival rate of less than 9 % (Siegel et al., 2020). 
According to the record of incidence and mortality associated with PDAC, it is set to 
become the second leading cause of cancer-related death by 2030 (Rahib et al., 2014). 
In comparison to breast and lung cancer, where treatment and early detection 
approaches have led to a significant improvement in prognosis (Andre and Pusztai, 2006; 
Rudin et al., 2019; Tsao et al., 2015), PDAC has an invariably poor prognosis since there 
is no biomarkers available for the early diagnosis. Besides, PDAC is highly aggressive 
and metastatic, showing strong resistance to chemotherapies. One of the major 
biomedical challenge in the poor prognosis and treatment of PDAC is the complex tumor 
stroma heterogeneity. However, factors involved in promoting cross-talk between tumor 
and stromal cells in the microenvironment remain unresolved.  
1.1.1 Pathophysiology  
The pancreas is a soft and glandular organ that mainly consists of endocrine and exocrine 
functional units (Zhou and Melton, 2018). The endocrine pancreas is responsible for 
regulating metabolism in the body, for example by regulating the blood glucose level. The 
exocrine compartment consists of acinar and ductal cells, where the acinar cells secrete 
the digestive enzymes (e.g. amylase, lipases, and proteinases) and ductal cells transport 
the secretion of enzymes to the small intestine (Zhou and Melton, 2018). In general, there 
are rare tumors arising from the endocrine pancreas; however, mainly neuroendocrine 
tumors (Kleeff et al., 2016). Over 90% of pancreatic tumors originate from the exocrine 
pancreas, with pancreatic ductal adenocarcinoma (PDAC) being the predominant type of 
tumors (Hezel et al., 2006; Prinz, 2012). Most PDAC arise from the head of the pancreas 




1.1.2 Tumor initiation and progression 
The well-accepted PDAC progression model states that PDAC gradually develops from 
transformation of normal ductal epithelial cells to aggressive adenocarcinoma with the 
activation of certain oncogenes sequentially through the formation of well-defined 
precursor lesions called pancreatic intraepithelial neoplasia (PanIN-1 to 3) (Figure 1) 
(Hruban et al., 2001). PanIN-1 are lesions of flat or papillary architecture without any 
abnormalities. PanIN-2 lesions show enlarged and crowed nuclei, mild dysplasia with 
increased abnormalities and papillary architecture. PanIN-3 displays severe nuclear 
atypia, a high grade of dysplasia on the verge of carcinoma (Hruban et al., 2001). 
In PDAC, KRAS mutations are the prevalent alterations in more than 90% cases (Olive 
and Tuveson, 2006). Further, mutations in KRAS are one of the earliest genetic events, 
which is essential for the initiation and development of PDAC (Kanda et al., 2012; 
Hingorani et al., 2003). KRAS protein is a Guanosine triphisphatase (GTPase), which is 
part of RAS/MAPK pathway (Iguchi et al., 2016). KRAS mutation leads to continuously 
binding of GTP in regardless of external stimulus and therefore promote tumor cell growth 
(Vigil et al., 2010; Waters and Der, 2018). Besides KRAS mutations, TP53, CDKN2A and 
SMAD4 are also considered as the most important driver mutations, which occur, in 
pancreatic carcinogenesis (Kleeff et al., 2016). For instance, CDKN2A encodes 
p16INK4A protein that binds and inactivates CDK4, leading to cell cycle G1 arrest 
(McWilliams et al., 2011; Zhao et al., 2016). On the other hand, CDKN2A encodes 
p16ARF for stabilizing p53 (Bartsch et al., 2002). Alterations in CDKN2A are observed in 
PanIN-2 lesions and more than 90 % of PDAC tumors (Wilentz et al., 1998). TP53 is 
inactivated in more than 70 % of PDAC (Puleo et al., 2018; Chan-Seng-Yue et al., 2020). 
Loss of TP53 favours tumor cell proliferation and survival as well as promoting additional 
unfavourable genetic alterations (Koorstra et al., 2009). Similarly, tumor suppressor 
SMAD4 is altered in more than 55 % late stage PDAC (Iacobuzio-Donahue, 2012). 
Mechanistically, SMAD4 is involved in transforming growth factor (TGF-β) mediated 
signaling pathway (Iacobuzio-Donahue, 2012; Xia et al., 2015). During the progression of 





Figure 1. PDAC progression model. Illustration diagram of PDAC development from normal 
pancreatic tissue to PDAC through PanIN lesions (PanIN-1 to PanIN-3) and sequential activation 
of driver mutations KRAS, CDKN2A, TP53 and SMAD4. 
 
1.1.3 Therapeutic strategies of PDAC 
Due to the highly aggressive nature of PDAC, surgery is the only potentially curative 
therapeutic option (Hartwig et al., 2013). However, majority of patients are not amenable 
to surgery due to locally advanced or metastatic PDAC at the time of diagnosis. In fact, a 
large number of PDAC patients faced tumor recurrence post-surgical resection (Onoue 
et al., 2004). Nevertheless, the therapeutic strategies for PDAC have improved in the last 
decades, which has led to an increased 5-year survival from 11 % to 21 % post-surgery 
and chemotherapy (Strobel et al., 2019).  
Gemcitabine is the most commonly used chemotherapeutic drug in the clinical settings 
for the treatment of PDAC patients (Burris et al., 1997). At the biochemical level, 
deoxycytidine, which is an active molecule of gemcitabine, converts into active metabolite 
that interferes with DNA synthesis and consequently inhibits tumor growth (Mini et al., 
2006). Notably, American Society of Clinical Oncology (ASCO) recommended 
gemcitabine, together with capecitabine for resectable tumors (Khorana et al., 2017). A 




5-year survival rate of resected PDAC patients improved from 25.5 to 28.0 months with 
gemcitabine and capecitabine combined therapy compared to gemcitabine alone 
(Neoptolemos et al., 2017).  However, the clinical outcome of adjuvant chemotherapeutic 
agents for the borderline resectable or unresectable tumors remain disappointing. Thus, 
neoadjuvant therapy emerged as an option for the borderline resectable or unresectable 
tumors, i.e. FOLFIRINOX treatment led to a conversion from unresectable stage to 
borderline or even resectable tumors (Nitsche et al., 2015; Petrelli et al., 2015).  
For unresectable patients, chemotherapies remain the only option. For instance, 
combination of gemcitabine and nab-paclitaxel clinically applied as the first-line therapy 
for PDAC patients (Goldstein et al., 2015). An alternative to gemcitabine plus nab-
paclitaxel for clinically fit patients is the FOLFIRINOX regimen, which is a combination 
therapy consisting of 5-FU, leucovorin, irinotecan, and oxaliplatin (Vaccaro et al., 2011). 
Notably, this combination significantly improves the outcome of metastatic patients when 
compared with monotherapy gemcitabine (11.1 vs 6.8 months) (Conroy et al., 2011). A 
phase III clinical trial reported that nanoliposomal irinotecan in combination with 5-FU/FA 
significantly improved the survival rate (6.1 vs 4.2 month) of those metastatic PDAC 
patients who had previously received gemcitabine-based therapy (Wang-Gillam et al., 
2016). It is worth noting that, the second-line therapeutic option is determined based on 
the treatment applied in the first-line therapy as well as the patient performance 
(Ellenrieder et al., 2016). 
Recently, the phase III POLO clinical trial reported that PARP inhibitor Olaparib improved 
progression-free survival. It is now recommended for the patients with germline BRAC 
mutation (Golan et al., 2019). Besides, immune therapy studies have shown significant 
improvement in survival rate in several cancer types. For instance, blockage of immune 
checkpoint T lymphocyte-associated antigen 4 (CTLA4) has been approved for clinical 
application in advanced melanoma (Hodi et al., 2010). Anti- programmed death 1 (PD1) 
and PD1 ligand (PDL-1) therapies were reported to be successfully established in multiple 
cancers including melanoma, lung cancer, and kidney cancer (Brahmer et al., 2015; 
Garon et al., 2015; Larkin et al., 2015; Motzer et al., 2015; Topalian et al., 2014). 




immune regulation in the pancreatic tumor microenvironment (TME) (Neoptolemos et al., 
2018). 
Taken together, it is still very challenging to treat PDAC. Hence, extensive studies in the 
molecular subtyping are urgently needed to understand aggressive features and 
chemoresistance of PDAC. As in breast and lung cancer, subgrouping patients by 
molecular characteristics may benefit PDAC patients through optimized/personalized 
therapeutic approaches (Andre and Pusztai, 2006; Rudin et al., 2019; Tsao et al., 2015). 
1.2 Molecular subtypes of PDAC 
In recent years, considerable progress has been made in identifying molecular subtypes 
of PDAC, which remarkably improved the molecular insights of this grave disease (Table 
1). In 2011, Collisson et al. defined three molecular subtypes of PDAC known as classical 
(CLA), quasi-mesenchymal (QM) and exocrine-like subtypes (Collisson et al., 2011), 
which is a landmark study that contributes to uncover the heterogeneity of PDAC. By 
performing microarray gene expression analysis in resected PDAC patient tumors, they 
identified a 62 gene signatures that allows clustering of tumors into certain subtypes 
(Collisson et al., 2011). The CLA subtype is found to be associated with high levels of 
epithelial gene signatures, while QM subtype has a high expression of mesenchymal 
genes and exhibit poor survival rate compared to CLA subtype. Multiple human and 
murine PDAC cell lines were able to delineate the CLA and QM subtypes (Collisson et 
al., 2011), which, in future, could be utilized as a model for studying subtype-specific 
therapeutic strategies.  
After 4 years, another work in PDAC subtyping was conducted by Moffitt et al. (Moffitt et 
al., 2015). In their study, stroma compartment was taken into consideration and virtual 
microdissection approach was utilized in primary and metastatic tumors to distinguish 
between stromal and tumor-specific gene sets. Tumor epithelial compartment can be 
characterized into classical (CLA) and basal-like (BL) subtypes, which have been shown 
to overlap with the previous Collisson subtypes (Collisson et al., 2011). In contrast to the 




subtyping of epithelial-tumor compartments, Moffitt et al. molecularly characterized 
stromal compartments into two different subtypes: the normal and activated stroma. The 
so-called normal stroma corresponds to better prognosis, while activated stroma shows 
inflammatory signature and links to poor prognosis. In comparison to Collisson et al., the 
Moffitt et al. study has higher prognostic relevance since stroma subtypes were included 
and showed distinct tendencies. 
In 2016, Bailey et al. performed RNA sequencing (RNA-seq) analysis in 96 bulk tumors 
to explore the transcriptional network and revealed four subtypes called progenitor, 
immunogenic, aberrantly differentiated endocrine exocrine (ADEX), and squamous 
(Bailey et al., 2016). The progenitor subtype is linked to the transcriptional programs, 
which are essential for endoderm fate determination. The immunogenic subtype shares 
high similarities with progenitor, and regulates pathways involving in antigen presentation 
and B cell signaling. While ADEX tumors exhibit molecular signatures associated with 
pancreatic differentiation and development (Bailey et al., 2016). The most aggressive 
squamous subtype is associated with metabolic reprogramming, hypoxia, as well as 
inflammation. Furthermore, The Cancer Genome Atlas (TCGA) research network 
confirmed a significant overlap of the squamous to the BL subtype (Cancer Genome Atlas 
Research Network, 2017), previously identified by Moffitt et al. Besides, previously 
defined CLA subtype (Collisson et al., 2011 and Moffitt et al., 2015) that largely 
overlapped with the progenitor subtype (Bailey et al., 2016). However, ADEX and 
immunogenic subtypes were found to have less tumor purity, i.e. a high degree of 
contamination with non-neoplastic cells. 
Puleo et al. conducted a microarray analysis in a large cohort of patient samples from 
309 paraffin embedded PDAC tissues (Puleo et al., 2018). An unsupervised analysis 
concluded five subtypes: pure classical, immune classical, desmoplastic, stroma 
activated, and pure basal-like. With a high cellularity, tumors were classified into pure 
classical and pure basal-like subtypes. Notably, they identified a significant association 
of pure classical to well differentiated/low grade tumors. In contrast, pure basal-like 
subtype is linked to poorly differentiated/high grade tumors. The overall survival rate of 




In addition, most recent work from Chan-Seng-Yue et al. suggested the intra-subtype 
heterogeneity within the previously existing CLA and BL PDAC subtypes (Chan-Seng-
Yue et al., 2020). Overall, this study overcomes the limitation of the previous studies that 
only have access to resected tumor tissues where the genomic signatures from high-
grade tumors or advanced stage tumors could be underrepresented. The transcriptomic 
based analysis of the primary and metastatic PDAC tumors identified classical-A, 
classical-B, hybrid, basal-like A, and basal-like B subtypes (Chan-Seng-Yue et al., 2020). 
Interestingly, this study suggested that basal-like A subtype is the most aggressive 
phenotype, which occurs in very late stage tumors, conferring high resistance to 
chemotherapy and consequently worse prognosis. Basal-like B was found predominantly 
in the resectable PDAC tumors. However, CLA and BL subtypes were coexisted 
intratumorally (Chan-Seng-Yue et al., 2020), suggesting the highly heterogeneous 
phenotype of PDAC. 
 
Table 1. PDAC subtypes. 
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Basal-like-A is highly 
resistant to chemotherapy, 
associated with extremely 
poor prognosis 
ADEX, Aberrantly differentiated endocrine exocrine; QM, Quasi-mensenchymal; RNA-seq, RNA sequencing; TCGA, 
The Cancer Genome Atlas. 
 
Altogether, these transcription-based studies suggest the two most clinical-relevant 
PDAC molecular subtypes: the CLA subtype, characterized by expression of epithelial 
markers and corresponding to favorable prognosis, and the BL subtype, associated with 
high levels of epithelial-to-mesenchymal (EMT) signatures and correlating to unfavorable 
prognosis (Figure 2). Indeed, these subtypes show different vulnerabilities to 
chemotherapy: in particular, BL tumors show a high degree of chemoresistance, 
promoting a poor patient prognosis. The COMPASS trial reported by Aung et al. showed 
that the CLA subtype patients respond better to either modified FOLFIRINOX or 
gemcitabine/ plus nab-paclitaxel chemotherapy, while BL subtype still continuously 






Figure 2. Characteristics of CLA and BL PDAC subtypes. PDAC can be robustly characterized 
into two subtypes: CLA and BL subtype. They display distinct tumor histology features, 
chemoresistance as well as prognosis. 
 
1.3 Subtype-specific regulatory network 
Despite having defined the prognostically relevant CLA and BL subtypes, the regulatory 
networks within tumor cells, especially the key transcription factors (TFs) that control 
subtype-specific gene programs and maintain their cellular identity, remain largely 
unknown. An initial study comprehensively addressed the subtype-specific transcriptional 
regulation as well as control of lineage-specific markers in PDAC phenotypic identity 
(Diaferia et al., 2016). By performing RNA-seq analysis in established human PDAC cell 
lines, they identified a set of genes corresponding to high- and low-grade tumors, 
reflecting CLA and BL tumors respectively. Among those, KLF5, ELF3, HNF1B, as well 
as JUNB were mainly expressed in low-grade tumors. In contrast, high-grade tumors 
showed abundant expression of ZEB1, GATA2 and ETV5 (Diaferia et al., 2016). Besides 
these grade-specific markers, ‘GATA6’ emerged as a potential biomarker for the CLA 
subtype identity in PDAC patient tumors (Aung et al., 2018; Chan-Seng-Yue et al., 2020).  
PDAC patients with high-grade tumors expressed significantly low GATA6, supporting by 
RNA in situ hybridization assay in the tumors (Aung et al., 2018). Further, to determine 




mediated GATA6 silencing in multiple low-grade PDAC cell lines (Martinelli et al., 2017). 
Intriguingly, genetic inactivation of GATA6 led to loss of epithelial-lineage markers (e.g. 
E-cadherin) and gain of the EMT-related markers such as vimentin in the GATA6-
depleted PDAC cells. Furthermore, cells acquired significantly more invasive and BL 
phenotypic identity upon GATA6 silencing. Furthermore, patients with low expression of 
GATA6 have shorter survival and a poor response to chemotherapy compared to those 
who have medium or high levels of GATA6 (Martinelli et al., 2017, Aung et al 2018). 
Recently, HNF4A, a low-grade lineage TF found to be an essential player in maintaining 
CLA subtype identity (Brunton et al., 2020). NHF4A depleted cells showed induction of 
BL phenotype gene signature, with upregulation of gene sets involved in WNT, insulin, as 
well as phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathways. Besides, loss of 
HNF4A led to activation of BL-associated metabolic signatures (Brunton et al., 2020).  
Overall, identification of low-grade/CLA-specific TF (i.e. GATA6) turned out to be a 
significant tool for PDAC patient stratification. Similarly, several studies have focused on 
deciphering the gene regulatory network underlying BL phenotype. Notably, it has 
recently been shown that TFs such as GLI2 and TP63 (ΔNp63) maintain BL subtype 
identity (Adams et al., 2019; Somerville et al., 2018). GLI2 alone is sufficient to cause a 
switch from CLA to BL subtype in PDAC cells (Adams et al., 2019). Similarly, TP63 was 
also identified as a key factor that controls a transcription regulatory network supporting 
the squamous/BL phenotypic state. Moreover, ectopic expression of TP63 was shown to 
be sufficient to induce the reprogramming of TFs for the maintenance of a squamous 
differentiation in PDAC (Somerville et al., 2018). Whether and how lineage-specific TFs 
recruit chromatin regulators to shape PDAC subtype plasticity remain poorly understood. 
Recent studies have shown that chromatin regulator lysine demethylase 6A (KDM6) is 
required to maintain the CLA PDAC subtype identity both in vitro and in vivo (Andricovich 
et al., 2018). Pancreas specific loss of Kdm6a (Kras-Kdm6a-/- mice) displayed poorly 
differentiated histological features. Mechanistically, global gene expression profile 
showed that depletion of Kdm6a led to enrichment of EMT, pro-inflammatory, and 
response to hypoxia pathways, corresponding to BL phenotypic identity (Andricovich et 




Altogether, these studies have provided evidence for the mechanisms of regulation of 
PDAC subtypes. Here, we propose a model of lineage TFs determined subtype identity 
(Figure 3). By exploring the specific lineage markers, it will be possible to exploit clinical 
diagnostic markers as well as tailored therapeutic approaches.  
 
Figure 3. Proposed model of tumor-specific TFs in PDAC subtype maintenance. Lineage-
specific TFs and coregulators shape CLA and BL subtype identity.  
 
1.4 The tumor microenvironment  
The TME of PDAC has a significant impact on tumor initiation, progression, and 
metastasis (Hessmann et al., 2020). PDAC has a complex TME that consists of 
endothelial cells, cancer-associated fibroblasts (CAFs), tumor cells, extracellular matrix 
(ECM), immune cells, and soluble factors such as growth factors, cytokine, and 
chemokine (Figure 4). CAFs and Tumor-associated macrophages (TAMs) are two 
prominent components of the inflammatory TME. In most of the solid tumors, the 
existence of TAMs is associated with an unfavorable prognosis (Komohara et al., 2014; 
Zhang et al., 2012). In PDAC, high expression of macrophage signatures are associated 
with poor prognosis (Bailey et al., 2016). Single-cell analysis performed by Hosein et al. 
revealed that the population of TAMs dramatically increased at the late stage of the 
disease compared to the initial phase, indicating the correlation between macrophage 




that macrophage represses T cell activity to allow for tumor growth and is associated with 
the squamous phenotype (Candido et al., 2018). A subtype switch from squamous to 
progenitor could be seen upon macrophage depletion. In addition, the macrophage is 
found to inhibit the efficiency of gemcitabine by releasing pyrimidine nucleosides 
(Halbrook et al., 2019). Targeting macrophage via inhibitor against the colony stimulating 
factor 1 receptor (CSF1R) could restore the effect of gemcitabine (Candido et al., 2018).  
 
Figure 4. Stromal immune microenvironment of PDAC. The TME of PDAC comprises diverse 
cell types including tumor cell, endothelial cell, CAFs, extracellular matrix, soluble factors, as well 
as immune cells, such as T cell, Treg cell, TAMs and myeloid-derived cell. 
 
1.4.1 Inflammatory tumor stroma microenvironment  
1.4.1.1 Role of inflammation in tumor progression 
Inflammatory microenvironment is evidenced to be an essential content for almost all 




diseases increase the risk of cancer development, as in prostate cancer, ovarian cancer, 
gastric cancer, intestinal cancer, as well as bladder cancer (Grivennikov et al., 2010; 
Mantovani et al., 2008). Inflammation has a significant impact on PDAC tumor 
development and progression (Guerra et al., 2007; Rhim et al., 2012., Singh et al 2015). 
Apart from smoking and alcohol consumption, chronic pancreatitis is considered the main 
risk factor for developing PDAC (Yadav and Lowenfels, 2013). Inflammation is initially 
induced in the context of pancreatitis to prevent the loss of homeostasis and promote 
tissue regeneration. For example, acinar cells transform into duct-like architecture termed 
acinar-to-ductal metaplasia (ADM) in response to inflammatory cues (Liou et al., 2013). 
Normally, ADM is highly plastic and reversible to allow the repair of pancreatic injury 
(Rooman and Real, 2012; Stanger and Hebrok, 2013). However, in the context of cancer, 
with the constitutively activation of oncogene KRAS and chronic presence of inflammatory 
cytokines, acinar cell displays a high degree of abnormalities and develops into full-blown 
PDAC (Logsdon and Ji, 2009). 
Rihm et al. have unveiled a significant role of inflammation in pancreatic tumor formation 
and dissemination (Rhim et al., 2012). In the metastatic PDAC mouse model, EMT and 
invasiveness were extensively surrounded by inflammatory cells. Cerulein-induced 
inflammation in mice resulted in accelerated formation of PanIN lesions and increased 
circulating cells. For the confirmation of inflammation induced EMT, mice received anti-
inflammatory drug, which showed a general reduction of inflammation and feebly 
developed PanIN lesions (Rhim et al., 2012). Based on these data, we proposed a model 
that the external stimulus (e.g. cytokines or chemokines) from the inflammatory 
microenvironment might induce PDAC subtype switch, which, in turn, lead to disease 





Figure 5. Inflammation-driven subtype shaping in PDAC. Inflammatory cytokines and 
chemokines secreted from the TME might induce formation of an aggressive subtype.   
 
A recent study by Cobo et al. showed cell-autonomous reprogramming driven by 
inflammation that regulated the differentiation of acinar cells and contributed to the 
development of PDAC (Cobo et al., 2018). The orphan nuclear receptor NR5A2 is 
involved in pancreatic embryonic development and controls acinar cell differentiation 
(Hale et al., 2014). In PDAC patients, there is a strong correlation of low NR5A2 
expression to the patients who had chronic pancreatitis previously (Cobo et al., 2018). In 
Nr5a2 wild type mice, NR5A2 binds on genes that maintain acinar cell differentiation. 
Interestingly, NR5A2 shifts its binding from acinar-related genes to inflammatory genes 
in Nr5a2+/- pancreata, via interaction with cJUN/AP-1 transcription factor. Caerulein-
treated (induce pancreatitis) wild type mice also exhibited a similar inflammatory profile. 
Notably, inhibition of cJUN TF led to abrogation of this transcriptional switch, thus, 
inflammatory gene expression was halted. Mechanistically, NR5A2 cooperates with 
Nr0b2 to represses cJUN activity to maintain low inflammation and favorable outcome 
(Cobo et al., 2018). Therefore, NR5A2 loss leads to high induction of cJUN and further 




1.4.1.2 Tumor stroma microenvironment in disease progression 
Cytokines are key soluble factors in connecting inflammation to cancer (Grivennikov et 
al., 2010). They play a crucial role in modulating cellular components in TME, especially 
the interactions between epithelial and stromal immune compartment (Shadhu and Xi, 
2019). In PDAC microenvironment, the dynamic cross-talk between tumor cells and 
inflammatory cells is largely determined by cytokines. Inflammatory cells (e.g. TAMs and 
CAFs) are the main source of cytokine production, secreting IL-1, IL-6, IL-10, TGF-β and 
TNFα to influence tumor cell behavior and promote PDAC progression (Biffi et al., 2019; 
Huang et al., 2019; Ikemoto et al., 2000; Karakhanova et al., 2015; Zhao et al., 2016).  
TNFα is a well-known master regulator of inflammation and immune response. It is a type 
II transmembrane protein and is released by the cleavage of a converting enzyme at the 
site between Ala76-Val77 (Wajant, 2009). TNFα can be produced in multiple cell types 
including macrophage, activated monocyte, activated T cell, dendritic cell, nature killer 
(NK) cell, microglia, as well as astrocyte (Zidi et al., 2010). TNFR1 (p55) and TNFR2 (p75) 
were identified as receptors for TNFα. TNFR1 is expressed ubiquitously on all cell types; 
however, TNFR2 is restricted to endothelial and immune cells (Sethi et al., 2008). While 
extensive efforts have been made to study the role of TNFα in regulating inflammation 
and inflammatory disease, the functional relevance of TNFα in tumor progression and 
drug resistance have not been fully addressed. 
Lind et al. revealed a significant role of TNFR1 in skin cancer development (Lind et al., 
2004). Squamous carcinoma mouse model develops rather quickly microscopically skin 
changes in 3 weeks, with massive immune cell infiltration. However, Tnfr1-/- mice do not 
give rise to skin tumor and inflammation (Lind et al., 2004), suggesting that TNFR1-
mediated signaling pathway is involved in the development of skin cancer. In breast 
cancer, over half of the studied patients (105 patients in total) were found to have TNFα 
abundance in their tumor tissues characterized by immunohistochemistry staining. Tumor 
cells isolated from patients with high- and low- expression of TNFα were subjected to 
doxorubicin (DOX) treatment. It showed that TNFα-high expressing cells confer more 




PDAC, TNFα induces invasive capacities of the PDAC cells and secretions of IL-8 and 
MMP9 (Egberts et al., 2008). Administration of TNFα in vivo leads to increased tumor 
growth and metastasis. However, blocking TNFα in combination with chemotherapy 
reduces tumor volume and metastasis in PDAC models (Egberts et al., 2008). Moreover, 
Zhao et al. has reported that high levels of TNFα is associated with an unfavourable 
prognosis in PDAC patients (Zhao et al., 2016). 
1.4.2 Reciprocal interaction between stromal and tumors cells in PDAC 
prognosis  
In the TME, studies have shown that the co-existence of stromal cells within tumor cells 
linked to distinct prognosis in PDAC. Moffitt et al. showed that coexisting activated stroma 
within BL tumors are linked to poor prognosis (Moffitt et al., 2015). However, Puleo et al., 
showed that activated stroma within BL tumors led to better survival of PDAC patients 
(Puleo et al., 2018). Therefore, further studies are required to address the stromal 
immune determined PDAC subtype identity and prognosis. It is known that tumor cells 
are capable of changing their phenotype in response to certain inflammatory factors 
secreted by the stromal compartment, and vice versa (Mantovani et al., 2008). TME can 
determine the tumor cell differentiation, as implanting identical patient-derived organoids 
directly into ducts or interstitial space of the pancreas, which induces either an intraductal 
or a stroma TME, respectively (Miyabayashi et al., 2020). It turned out that the EMT 
marker vimentin (VIM) was highly elevated in the tumors that grow in a stromal TME 
compared to the ones grown in intraductal TME. Interestingly, those organoids were also 
showed to transform stromal cells to gain more invasive properties with the induction of 
EMT, and specifically, TGF-β and WNT (Miyabayashi et al., 2020). Similarly, another 
study evidenced that TME shapes the phenotypic status of organoids regardless of the 
genotype (Raghavan et al., 2020). In addition, the soluble factors from TME induce cell 
identity shift concordant to gain of BL genes and loss of organoid-related genes 
(Raghavan et al., 2020). 
In summary, these studies highlighted the importance of the dynamic interplay between 




and interact with its microenvironment remains poorly understood. Hence, molecular 
understanding of the heterotypic interactions within TME could provide a novel insight 
into the development of specific therapeutic strategies.  
1.5 Aims of the study 
Recent studies have invested tremendous efforts in molecular classification of PDAC. In 
particular, the transcriptional profiling of TME indicates a significant correlation of stroma 
inflammatory gene signatures to distinct clinical outcomes (Singh et al., 2019; Moffitt et 
al., 2015; Maurer et al., 2019; Puleo et al., 2018). Markedly, the stromal immune 
compartment within differential epithelial tumor subtypes determine the therapeutic 
response and prognosis in PDAC (Singh et al., 2019; Moffitt et al., 2015). 
Inflammatory cytokines are mediators of the cross talk between tumor cells and 
microenvironment. For instance, TNFα expression has been shown to be negatively 
associated with PDAC patient survival (Zhao et al., 2016). Studies have shown that PDAC 
tumor cells can change the plasticity through transcriptional reprogramming particularly 
in response to inflammatory cue (Rhim et al., 2012; Singh et al 2015). Therefore, we 
proposed that TNFα might change the plasticity of PDAC cells and mediate subtype 
switch from CLA to BL to accelerate the progression of PDAC. 
In this study, we aimed to characterize the role of TNFα in PDAC subtype switch as well 
as examine the underlying mechanisms and the potential of selective pathway 
interference in PDAC therapy. Our specific aims were as follow: 
1. To investigate the role of TNFα in PDAC subtype maintenance and disease 
aggressiveness;  
2. To elucidate the mechanism of TNFα-dependent transcriptional reprogramming in 
PDAC subtype switch; 
3. To explore the intrinsic factors which contribute to PDAC subtype identity and 
aggressiveness; 





5. To evaluate the therapeutic interventions against TNFα-mediated inflammation- 
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2. Material and methods 
2.1 Material  
2.1.1 Lab equipment 
Table 2. Lab equipment.  
Equipment  Company  
Agarose electrophoresis chamber  Peqlab Biotechnologie, Erlangen, Germany 
Anesthetic vaporizer-Sigma delta Penlon, Abingdon, UK 
Arium pro ultrapure water system Sartorius, Göttingen, Germany 
Aspirator with trap flask (Grant bio FTA-1) Grant Instruments, Cambridge, UK 
Bioanalyzer 2100 Agilent Technologies, Santa Clara, USA 
Bioruptor Pico sonication device   Diagenode, Liege, Belgium 
Centrifuge-Perfectspin 24R (refrigerated) Peqlab Biotechnologie, Erlangen, Germany 
Centrifuge-Heraeus Megafuge 16 / 
Multifuge X1R 
Thermo Fisher Scientific, Waltham, USA 
CO2 incubator (HERAcell 240i) Thermo Fisher Scientific, Waltham, USA 
Cold plate-Histocore Arcadia c Leica Biosystem, Wetzlar, Germany 
Fluid Aspiration System – BVC Control Vacuubrand, Wertheim, Germany 
Fluoview F1000 Confocal Microscope Olympus, Shinjuku, Japan 
Freezer 4 ºC Liebherr, Bulle, Switzerland 
Freezer -20 ºC Liebherr, Bulle, Switzerland 
Freezer -80 ºC Sanyo Electric, Japan 
Heated Paraffin Embedding Module – 
EG1150 H with cold plate 
Leica Biosystems, Nussloch, Germany 
gentleMACS dissociator Miltenyi Biotec, Bergisch Gladbach, Germany 
Ice flaker-AF80 Scotsman, Edinburgh, UK 
INTAS UV System Intas Science Imaging Instruments, Göttingen, 
Germany 
Liquid nitrogen cell storage canister-
Biocane 47 
Thermo Fisher Scientific, Waltham, USA 
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Light microscope “BX43” Olympus, Shinjuku, Japan 
Microplate reader PHOmo / LUmo Autobio Labtec Instruments, Zhengzhou, China 
Microscope-Axiovert 25 Carl Zeiss, Oberkochen, Germany 
Microwave heat pad for animals- 
snuggleSafe 
SnuggleSafe Lenric C21, West Sussex, UK 
Nano Photometer-P330 Intas Science Imaging, Göttingen, Germany 
Nalgene Mr. Frosty freezing container Thermo Fischer Scientific, Waltham, USA 
Neubauer counting chamber Brand, Wertheim, Germany 
Paraffin tissue embedder (EG1150H) Leica Biosystems, Wetzlar, Germany 
Perfect Spin 24Plus Microcentrifuge VWR/Peqlab, Erlangen, Germany 
Perfect Spin 24R Refrigerated 
Microcentrifuge 
VWR/Peqlab, Erlangen, Germany 
pH meter-FiveEasy Plus FEP20 Mettler Toledo, Schwerzenbach, Switzerland 
Plate Spinner-PerfectSpin P Peqlab Biotechnologie, Erlangen, Germany 
PowerPac HC High-Current Power Supply Bio-Rad Laboratories, Hercules, USA 
Qubit Fluorometer-Q32854 Invitrogen, Karlsruhe, Germany 
StepOnePlus real-time PCR system Applied Biosystems, Foster City, USA 
Rotary Microtome-RM2265 Leica Biosystems, Nussloch, Germany  
Shaker-Duomax 1030 Heidolph Instruments, Schwabach, Germany 
Shaver-ER-PA10 Panasonic Corporation, Osaka, Japan 
StepOnePlus Real-Time PCR System ThermoFisher Scientific, Waltham, USA 
Tissue dehydration machine Leica Biosystems, Nussloch, Germany 
Trans-Blot Turbo Transfer System Bio-Rad Laboratories, Hercules, USA 
Tube Rotator Stuart, Staffordshire, UK 
Ultrasound scanner Vevo 2100 Fujifilm VisualSonics, Toronto, Candada 
Vacuum pump: BVC Control Vacuumbrand, Wertheim, Germay 
VS120 virtual slide microscope Olympus, Shinjuku, Japan 
Vortexer Lab Dancer Ika-Werke, Staufen, Germany 
Vortexer Vornado Benchmark Scientific, Edison, USA 
Water bath WNB 14 Memmert, Schwabach, Germany 
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Weighing balance Sartorius, Göttingen, Germany 
 
2.1.2 Consumables 
Table 3. Consumables. 
Consumables  Company  
Cell culture inserts – 8 µm pore size (BD 
353097) 
Sarstedt, Nümbrecht, Germany 
Cell scraper 25 cm Sarstedt, Nümbrecht, Germany 
Centrifuge tube (15/50 mL) Sarstedt, Nümbrecht, Germany 
Cryotube 1.5 mL Sarstedt, Nümbrecht, Germany 
Embedding cassettes Th. Geyer, Renningen, Germany 
Eye and nose ointment - Bepanthen Bayer Vital, Leverkusen, Germany 
Glass coverslips (24×32, 24×60) Menzel, Braunschweig, Germany 
Hair removal cream-Veet RB Healthcare UK, Hull, UK 
Injection needle (sterile) B.Braun, Melsungen, Germany 
Insulin syringes 30G-BD Micro-Fine + 
Demi 
Becton, Dickinson and Company, Franklin 
Lakes, USA 
Membrane filter 0.45 µm Merck Millipore, Billerica, USA 
MicroAmp optical 96-well reaction plate Applied Biosystems, Foster City, USA 
Microtome blade Feather, Osaka, Japan 
Microtube (0.5/1.5/2 mL) Sarstedt AG & Co., Nuembrecht, Germany 
Nitrocellulose membrane GE Healthcare Life Sciences, Marlborough, USA 
Optical adhesive covers  Applied Biosystems, Foster City, USA  
Parafilm Pechiney Plastic Packaging, Menasha, USA 
PCR tubes Sarstedt, Nümbrecht, Germany 
Scalpel Feather, Osaka, Japan 
Serological pipette (2/5/10/25 mL) Greiner Bio-One, Frickenhausen, Germany 
Syringe (1 mL) BD Plastic, Madrid, Spain 
Syringe (5/10/20 mL) B.Braun, Melsungen, Germany 
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Labsolute Sterile syringe Filter (0.2 µm) Th.Geyer Ingredients, Höxter, Germany 
TC dish 100 Sarstedt, Nümbrecht, Germany 
TC flask (T25/75/175) Sarstedt, Nümbrecht, Germany 
TC multiwell plates (6/12/24 wells) Greiner Bio-One, Frickenhausen, Germany 
Thick blot filter paper Bio-Rad, Hercules, CA, USA 
Tissue cassette Sanowa, Leimen, Germany 
Ultrasond gel Asmuth Medizintechnik, Minden, Germany 
Wound clips-Reflex 9 CellPoint Scientific, Gaithersburg, USA 
 
2.1.3 Chemicals and reagents 
Table 4. Chemicals and reagents. 
Chemical / Reagents Company 
6x DNA Loading Dye Thermo Fisher Scientific, Waltham, USA 
Acrylamide solution (30%/0.8%) AppliChem, Darmstadt, Germany 
Acetic acid 100% p.A. AppliChem, Darmstadt, Germany 
Agarose Nippon Genetics Europe, Düren, Germany 
Agarose protein A beads, fast flow Merck Millipore, Billerica, USA 
Ampicillin Carl Roth, Karlsruhe, Germany 
β-Mercaptoethanol Merck, Darmstadt, Germany 
Bromophenol blue Sigma-Aldrich, St. Louis, USA 
Bradford protein assay Bio-Rad, Hercules, USA 
Bovine serum Albumin Sigma-Aldrich, St. Louis, USA 
Chloroform p.a.  Th. Geyer, Renningen, Germany 
Citric acid monohydrate Carl Roth, Karlsruhe, Germany 
Collagen I, rat tail Enzo Life Sciences, Lörrach, Germany 
Dimethyl sulfoxide  Sigma-Aldrich, St. Louis, USA 
Disodium phosphate  Carl Roth, Karlsruhe, Germany 
Dithiothreitol  Sigma-Aldrich, St. Louis, USA 
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EDTA Merck Millipore, Billerica, USA 
EGTA Sigma-Aldrich, St. Louis, USA 
Eosin Y solution, aqueous Sigma-Aldrich, St. Louis, USA 
Epidermal growth factor  Sigma-Aldrich, St. Louis, USA 
Ethanol absolute p.a. Th. Geyer, Renningen, Germany 
Formaldehyde (37%) Sigma-Aldrich, St. Louis, USA 
Formaldehyde solution (4%), buffered Merck, Darmstadt, Germany 
FastGene 100 bp DNA marker Nippon Genetics Europe, Düren, Germany 
GeneRuler 1 kb DNA ladder Thermo Fisher Scientific, Waltham, USA 
Glycine  Carl Roth, Karlsruhe, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
HEPES Carl Roth, Karlsruhe, Germany 
Hematoxylin Sigma-Aldrich, St. Louis, USA 
Hydrochloric acid  Carl Roth, Karlsruhe, Germany 
Hydrogen peroxide 30%  Carl Roth, Karlsruhe, Germany 
Isopropanol Sigma-Aldrich, St. Louis, USA 
Isoflurane AbbVie Deutschland, Wiesbaden, Germany 
iTaq Universal SYBR Green Supermix Bio-Rad, Hercules, CA, USA 
Immu-Mount Thermo Fisher Scientific, Waltham, USA 
(+)-JQ1 MedChemExpress, Monmouth Junction, USA 
Lipofectamine 2000 reagent Invitrogen, USA 
Lithium chloride Sigma-Aldrich, St. Louis, USA 
Matrigel  Abcam, Cambridge, UK 
Monosodium phosphate  Merck, Darmstadt, Germany 
NP-40 Thermo Fisher Scientific, Waltham, USA 
Non-fat milk powder Carl Roth, Karlsruhe, Germany 
Normal goat serum  Abcam, Cambridge, UK 
PageRuler Prestained Protein Ladder Thermo Fisher Scientific, Waltham, USA 
Paraffin Engelbrecht, Edermünde/ Besse, Germany 
Material and methods 
26 
 
Paraformaldehyde  Merck, Germany 
PBS Dulbecco, powder Biochrom, Berlin, Germany 
Phenylmethylsulfonyl fluoride Sigma-Aldrich, St. Louis, USA 
Pierce TM ECL Western Blotting Substrate Thermo Fisher Scientific, Waltham, USA 
Ponceau S solution Sigma-Aldrich, St. Louis, USA 
Protease inhibitor cocktail cOmplete Roche Diagnostics, Mannheim, Germany 
Protein Assay Dye Reagent Concentrate 
(Bradford reagent) 
Bio-Rad, Hercules, USA 
Rotimount  Carl Roth, Germany 
Roticlear  Carl Roth, Karlsruhe, Germany 
RotiPhenol/chloroform/isoamylalcohol 
(25:24:1) 
Carl Roth, Karlsruhe, Germany 
Saline (0.9 % NaCl) B.Braun, Melsungen, Germany 
siLentFect Lipid reagent Bio-Rad, Hercules, CA, USA 
Sodium chloride Merck, Darmstadt, Germany 
Sodium dodecyl sulfate Carl Roth, Karlsruhe, Germany 
Sodium deoxycholate Sigma-Aldrich, St. Louis, USA 
Sodium fluoride  Sigma-Aldrich, St. Louis, USA 
Sodium orthovanadate  Sigma-Aldrich, St. Louis, USA 
Trans-Blot Turbo 5x transfer buffer Bio-Rad Laboratories GmbH, Neuberg, 
Germany 
Tetrasodium pyrophosphate  Sigma-Aldrich, St. Louis, USA 
Tris-HCl Carl Roth, Karlsruhe, Germany 
Tris-base Carl Roth, Karlsruhe, Germany 
Triton X-100 Carl Roth, Karlsruhe, Germany 
TRIzol  ThermoFisher Scientific, Waltham, USA 
Tumor Necrosis Factor-α human Sigma-Aldrich, St. Louis, USA 
Tumor Necrosis Factor-α human PeproTech, Hamburg, Germany 
Tween-20 Sigma-Aldrich, St. Louis, USA 
Western Lightning ECL plus PerkinElmer, Waltham, USA 
Western Lightning ECL ultra PerkinElmer, Waltham, USA 
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Xylene AppliChem, Darmstadt, Germany 
 
2.1.4 Kits and plasmids  
Table 5. Kits used in the study.  
Kits  Company 
Bioanalyzer High Sensitivity DNA Analysis Kit Agilent Technologies, Santa Clara, 
California, USA 
CellTiter-Glo Luminescent Cell Viability Assay 
Kit 
Promega, Madison, USA 
ChIP DNA Clean & Concentrator kit  Zymo Research Europe, Freiburg, Germany 
Human Tumor Dissociation Kit Miltenyi Biotec, Bergisch Gladbach, Germany 
Human CCL2/MCP-1 Quantikine ELISA Kit R&D Systems, Minneapolis, USA 
Human TNFα Quantikine ELISA Kit R&D Systems, Minneapolis, USA 
iScript cDNA Synthesis Kit Bio-Rad Laboratories, Hercules, USA 
Mouse Cell Depletion Kit Miltenyi Biotec, Bergisch Gladbach, Germany 
Mouse TNFα Quantikine ELISA Kit R&D Systems, Minneapolis, USA 
Proteome Profiler Human Cytokine Array Kit R&D Systems, Minneapolis, USA 
Proteome Profiler Mouse Cytokine Array Kit, 
Panel A 
R&D Systems, Minneapolis, USA 
TruSeq RNA Library Prep Kit v2 Illumina, San Diego, USA 
 
Table 6. Plasmids used in the study.  
Plasmids  Company  
pMD2.G Addgene, Watertown, USA 
psPAX2 Addgene, Watertown, USA 
pCDH-TNFα Addgene, Watertown, USA 
pLKO.1 Addgene, Watertown, USA 
pMSCV-cJUN Addgene, Watertown, USA 
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pMSCV Addgene, Watertown, USA 
 
2.1.5 Drugs 
Table 7. Therapeutic drugs. 
Drug  Company  
Carprieve Norbrook Laboratories, Newry, UK 
Gemcitabine hydrochloride Sigma-Aldrich, St. Louis, USA 
Oxaliplatin Sigma-Aldrich, St. Louis, USA 
SN38 Sigma-Aldrich, St. Louis, USA 
Buprenorphine Bayer Vital, Leverkusen, Germany 
 
2.1.6 Nucleic acids 
2.1.6.1 siRNA oligonucleotides 
Table 8. siRNA used in the study. 
siRNAs Catalogue number  Company  
Negative control siRNA AM4611 Thermo Fisher Scientific, Waltham, USA 
cJUN #1 AM16704 Thermo Fisher Scientific, Waltham, USA 
cJUN #2 AM16708 Thermo Fisher Scientific, Waltham, USA 
BRD4 #1 J-004937-06-0002 Dharmacon, Lafayette, USA 
BRD4 #2 J-004937-07-0002 Dharmacon, Lafayette, USA 
 
2.1.6.2 Primers  
Table 9. Primers used for qRT-PCR (human). 
Gene  Forward primer Reverse primer 
XS13  TGGGACAGAACACCATGATG AGTTTCTCCAGAGCTGGGTTGT 
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cJUN  TCCAAGTGCCGAAAAAGGAAG CGAGTTCTGAGCTTTCAAGGT 
CCL2  CAGCCAGATGCAATCAATGCC TGGAATCCTGAACCCACTTCT 
 
Table 10. Primers used for ChIP-qPCR (human). 
Gene Forward primer Reverse primer 
CCL2 Promoter GCTTAATGGCACCCCATCCT GGGTCAGGACGAGACACTTTT 
CCL2 Enhancer  CCACTCACTTCTCTCACGCC CTGTCTGCCTCCCACTTCTG 
JUN Enhancer 1 TGCTGCTGTAGTGCACATTCT AGCACAGACCTTTCTGCTGG 
JUN Enhancer 2 ATGGACACTCATACATCAGAGAGC CTCAGCGTTCTCATCCGTGT 
JUN Enhancer 3 AGATTTCTGGGATCCGGCTTG CCGAGGAAAGCTCTTCGCAA 
CDH1 Promoter GGTGAACCCTCAGCCAATCAG AGTTCCGACGCCACTGAGA 
CDH1 Enhancer 1  GAGGCGGTATAGCCAGTTCC CTGCTCCTAGAGGCTCCTGA 
CDH1 Enhancer 2 GCTCGTGGAGGTTGTGTAGAA CAAGCAGAAGCTGACAAGTTCAA 
VIM Promoter ATCTGGGAGGCCCACGTAT TCTTTGCTCGAATGTGCGGA 
VIM Enhancer 1 ATTCCAAACCCCTGGATGATGTC GGATATGCTAGTGCTCTGACTGTT 
VIM Enhancer 2 AAGTTGCCTAAGTAACATCAATGCC GGGTCTGAAACCCAACACACT 
 
2.1.7 Antibodies and enzymes  
Table 11. Antibodies used for western blot.  
Antibodies  Dilution  Catalogue 
number 
Company  
BRD4 1:1000  ab128874 Abcam, Cambridge, UK 
CCL2  1:1000   MA5-17040 Invitrogen, Eugene, USA 
cJUN 1:1000  9165S Cell Signaling Technology, Danvers, USA 
E-Cadherin  1:1000  610181 BD Bioscience, San Jose, USA 
JUNB 1:1000  3753S Cell Signaling Technology, Danvers, USA 
JUND 1:1000  sc-74 Santa Cruz Biotechnology, Dallas, USA 
β-actin  1:40000  A3854 Sigma-Aldrich, St. Louis, USA 





1:6000  7076S Cell Signaling Technology, Danvers, USA 
Anti-rabbit IgG 
(HRP) 
1:6000  7074S Cell Signaling Technology, Danvers, USA 
 
Table 12. Antibodies used for flow cytometry analysis. 
Antibodies  Dilution  Catalogue number Company  
TNFα  1:20  502908 BD Bioscience, San Jose, USA 
IgG1, κ isotype control  1:20  553973 BD Bioscience, San Jose, USA 
 
Table 13. Antibodies used for immunofluorescence staining. 
Antibodies  Dilution  Catalogue 
number 
Company  
α-Amylase  1:100  3796 Cell Signaling Technology, Danvers, USA 
CCL2  1:1000   MA5-17040 Invitrogen, Eugene, USA 
CK19  1:100  ab52625 Abcam, Cambridge, UK 
CD45  1:50  550539 BD Biosciences, San Jose, USA 
CD68  1:50  ab955 Abcam, Cambridge, UK 
cJUN  1:100  9165S Cell Signaling Technology, Danvers, USA 
JUNB 1:100  3753S Cell Signaling Technology, Danvers, USA 
KRT81 1:100  sc-100929 Santa Cruz Biotechnology, Dallas, USA 
TNFα  1:50  ab1793 Abcam, Cambridge, UK 
Goat anti-rabbit IgG-
Alexa Fluor 488 
1:500  A-11008 Thermo Fisher Scientific, Waltham, USA 
Goat anti-mouse 
IgG-Alexa Fluor 568 
1:500  A-21124 Thermo Fisher Scientific, Waltham, USA 
Goat anti-rat IgG-
Alexa Fluor 647 
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Table 14. Antibodies used for ChIP. 
Antibodies  Catalogue number Company  
BRD4 antibody C15410337 Diagenode, Liege, Belgium 
cJUN antibody 9165S Cell Signaling Technology, Danvers, USA 
JUNB antibody 3753S Cell Signaling Technology, Danvers, USA 
H3K27ac antibody GTX128944 GeneTex, Alton Pkwy Irvine, USA 
Rabbit IgG C15410206 Diagenode, Liege, Belgium 
 
Table 15. Enzymes used in the study.  
Enzymes  Catalogue number Company  
Proteinase K A4392,0005 AppliChem, Darmstadt, Germany 
SuperScript II Reverse 
Transcriptase 
18064022 Thermo Fisher Scientific, Waltham, USA 
RNase A R6513 Sigma-Aldrich, St. Louis, USA 
 
2.1.8 Buffers 
2.1.8.1 Buffers for Western blot 
Table 16. Whole cell lysates (WCL) buffer. 








HEPES (pH7.5) 50 mM 
NaCl 150 mM 
EGTA 1 mM 
Glycine 10 % (v/v) 
Triton X-100 1 % (v/v) 
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Table 17. Laemmli buffer (5x). 




Tris (pH6.8) 225 mM 
Glycerin 50 % (v/v) 
SDS 5 % (v/v) 
DTT 100 mM 
Bromophenol blue 0.02 % (v/v) 
β-Mercaptoethanol 5 % (v/v) 
 
Table 18. Separating gel buffer and stacking gel buffer stocks. 
Name Components Final concentration 
Separating gel buffer stock 
(pH 8.8) 
Tris-base 1.5 M 
SDS 0.4 % (v/v) 
Stacking gel buffer stock 
(pH 6.8) 
Tris-base 0.5 M 
SDS 0.4 % (v/v) 
 
Table 19. Separating and stacking buffer working solution. 
Name  Components Volume 
 
Separating gel buffer  
10% 




Glycerol 4 mL 
Aqua dest 29.3 mL 
 
Separating gel buffer  
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15% Glycerol 4 mL 
Aqua dest 16 mL 
 
Table 20. Running buffer (10x). 
Name Components Final concentration 
 
Running buffer 
Tris-base 250 mM 
Glycerin 1.92 M 
SDS 1 % (w/v) 
 
Table 21. Transfer buffer (1L). 
Name Components Final concentration 
 
Transfer buffer 
5x Transfer buffer 200 mL 
Ethanol 200 mL 
Aqua dest 600 mL 
 
Table 22. TBS buffer (10x). 
Name Components Final concentration 
TBS buffer 
(pH 7.6) 
Tris-base 121.4 g 
NaCl 400.31 g 
Aqua dest 5 L 
 
Table 23. TBST buffer (10x). 




Tween 0.1 % (w/v) 
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Table 24. Blocking solution. 




Non-fat milk 5 % (w/v) 
 
2.1.8.2 Buffers for immunofluorescence staining 
Table 25. Citrate buffer.  
Name Components Final concentration 
Citrate buffer  
(pH 6.0) 
Citric acid monohydrate 2.1 g 
Aqua dest 1L 
 
Table 26. PB buffer. 
Name Components Final concentration 
PB buffer 
(pH 7.4) 
Monosodium phosphate 2.4 g 
Disodium phosphate 11.31 g 
Aqua dest 1 L 
 
Table 27. PBT buffer. 
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2.1.8.3 Buffers for Chromatin Immuno-Precipitation 
Table 28. Nelson buffer. 




NaCl 150 mM 
EDTA (pH 8) 20 mM 
Tris-HCl (pH 7.5) 50 mM 
NP-40 0.5 % 
Triton X-100 1 % 
NaF 20 mM 
 
Table 29. Gomes wash buffer. 
Name Components Final concentration 
 
 
Gomes wash buffer 
Tris–HCl (pH 8.5) 100 mM 
LiCl 500 mM 
NP-40 1 % (v/v) 
Sodium deoxycholate 1 % (w/v) 
NaF 20 mM 
EDTA 20 mM 
 
Table 30. Weinmann lysis buffer. 
Name Components Final concentration 
 
Weinmann lysis buffer 
Tris–HCl (pH 8.0) 50 mM 
EDTA 10 mM 
SDS 1 % (v/v) 
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2.1.9 Cell culture  
Table 31. Cell culture components. 
Components Company 
Bovine pituitary extract Sigma-Aldrich, St. Louis, USA 
Defined Keratinocyte-SFM Medium  ThermoFisher Scientific, Waltham, USA 
Dulbecco’s Modified Eagle Medium (DMEM) ThermoFisher Scientific, Waltham, USA 
Fetal calf serum (FCS) BioWest, Nuaillé, France 
Non-essential amino acids (NEAA) ThermoFisher Scientific, Waltham, USA 
Opti-MEM ThermoFisher Scientific, Waltham, USA 
PBS (-Ca/-Mg) ThermoFisher Scientific, Waltham, USA 
Penicillin-streptomycin solution Sigma-Aldrich, St. Louis, USA 
Roswell Park Memorial Institute (RPMI) 
1640 Medium 
ThermoFisher Scientific, Waltham, USA 
Polybrene Santa Cruz Biotechnology, Dallas, USA 
Puromycin Sigma-Aldrich, St. Louis, USA 
 
2.2 Methods  
2.2.1 Animal studies  
Animal experiments conducted in this study were approved by the University of Göttingen 
Central Animal-experimental Facility. 
KrasG12D;Trp53R172H;PdxCre (KPC) tumor tissues used in this study were provided by D. 
Spyropoulou (Department of Gastroenterology, GI Oncology & Endocrinology, UMG, 
Germany). In this model, Kras and Trp53 were both mutated specifically in the pancreas 
to induce PDAC as described previously (Hingorani et al., 2005). Histopathological 
classification of KPC tumors into well-to-moderately (W/M) (G1/G2), or poorly 
differentiated (G3/G4), was performed by expert pathologist P. Ströbel (Department of 
Pathology, UMG, Germany). 
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2.2.1.1 Orthotopic mouse models  
10-week old male NMRI-Foxn1nu/nu mice were used to generate orthotopic PDAC mouse 
models. Mice were injected with buprenorphine (0.1 mg/kg body weight) intraperitoneally 
(i.p.) 30 mins before transplantation. Mice were then kept on a warm plate and 
anesthetized by inhalation of 2.5 -3.5 % isoflurane in oxygen for surgery. Mice were 
subcutaneously injected with Carprieve (Norbrook Laboratories, Newry, UK; 5 mg/kg 
body weight) to ease the pain and inflammation immediately before surgery and one to 
two days after surgery if necessary. After confirming there was no stimuli reflection, skin 
was opened (~1 cm cut) on the left side of the mice where pancreas resides. 1 x 106 
PDAC cells (CAPAN1, CAPAN2, MiaPaCa2, and PANC1) were suspended in 15 µL 
culture medium and injected into the tail of the pancreas with an insulin syringe. 
For establishing the syngeneic KPC orthotopic mouse model, 10-week old male C57BL6J 
mice were anesthetized for hair removal before surgery, as described previously (Patzak 
et al., 2019). 3.5 x 104 KPC cells were injected into the tail of the pancreas. The rest of 
the procedures was carried out as above. 
2.2.1.2 Sonography  
Three weeks post transplantation, small animal high-resolution ultrasound was applied 
weekly to determine the tumor growth, as described previously (Patzak et al., 2019). 
Briefly, mice were put under isoflurane anesthesia and fixed with surgical tape so that 
each leg was restrained. Ultrasound gel was applied on the ventral body surface. 
Subsequently, ultrasound imaging was carried out using an Ultrasound scanner Vevo 
2100 (Fujifilm VisualSonics, Toronto, Canada). 
2.2.1.3 Treatment  
For TNFα studies, CAPAN1-transplanted mice were randomized into two groups. TNFα 
(PeproTech GmbH, Hamburg, Germany; 0.4 mg/kg body weight) was administrated via 
i.p. injection three times a week for in total three weeks. Aqua dest. was administrated in 
control mice.  
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For anti-TNFα studies, mice were randomized before treatment and administrated with 
anti-TNFα antibody (Hölzel Biotech, Köln, Germany; 10 µg/g body weight) or IgG isotype 
control (Hölzel Biotech, Köln, Germany; 10 µg/g body weight) three times a week after 10 
days of transplantation.  
For JQ1 studies, mice were randomized before treatment. 10 days after transplantation, 
JQ1 (MedChemExpress, Monmouth Junction, USA; 50 mg/kg body weight,) was 
administrated via i.p injection daily for three weeks. DMSO was administrated in control 
mice.  
2.2.1.4 Tissue harvesting  
Mice were euthanized by inhalation of CO2 and subsequent cervical dislocation. Whole 
pancreas, spleen, liver, and blood samples were collected. Samples of pancreatic tumor 
tissue were snap-frozen and stored at -80 ºC for further analysis. The rest of tissues were 
fixed in 4 % formaldehyde solution overnight. Blood samples in heparin tubes were 
centrifuged at 4000 X g for 10 min at room temperature. Serum was transferred to a 
microtube and stored at -80 ºC. 
2.2.1.5 Paraffin embedding and tissue sectioning  
Formaldehyde-fixed tissues were processed with an automatic tissue processer (Leica 
Biosystems, Nussloch, Germany) prior to paraffin embedding. The dehydration protocol 
is as follow: 75 min formaldehyde solution, 30 min 55 % ethanol, 45 min 85 % ethanol, 
60 min 96 % ethanol, 75 min 99 % ethanol, 70 min 99 % ethanol, 90 min 99 % ethanol, 
20 min xylene, 30 min xylene, 70 min xylene, 30 min paraffin, 45 min paraffin, 90 min 
paraffin. Tissues were then embedded in paraffin blocks. A microtome was used to 
section tissues at a thickness of 4 µm. Sections were kept at 37 ºC overnight before 
further staining.  
2.2.1.6 Hematoxylin and Eosin Staining  
Tissue sections were deparaffinized in xylene (twice for 30 min). After rehydration in and 
ethanol series (99 %, 95 %, 70 %, each 1 min), slides were kept in aqua dest. for 3 min. 
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Subsequently, slides were incubated in hematoxylin solution for 8 min followed by a 
washing step in running tap water for 7 min. Slides were then transferred shortly (5 s) in 
aqua dest. containing 0.2 % acetic acid followed by incubation in eosin solution (in 0.2 % 
acetic acid) for 15 s. Next, slides were dehydrated in increasing concentrations of ethanol 
(70 % for 30 s, 95 % for 1.5 min, 100 % for 2 min). Finally, slides were cleared in Roticlear 
and fixed with Rotimount. 
2.2.1.7 Tile image 
Whole tile image scans of H&E and IF staining were carried out using a VS120 virtual 
slide microscope (Olympus, Shinjuku, Japan), and resulting images were evaluated using 
cellSens Dimension software (Olympus, Shinjuku, Japan). 
2.2.1.8 Immunofluorescence (IF) staining and quantification 
IF was carried out as previously described (Singh et al., 2016). After deparaffinization 
with two times washing of xylene for 30 mins, sections were rehydrated in a descending 
order of ethanol (99 %, 96 %, 80 %, each 4 min). Antigen retrieval was achieved by 
keeping slides boiling in citrate buffer (pH 6.0) for 6 minutes in a microwave, then cooling 
down for 10 min at room temperature. Subsequently, sections were kept on ice for 20 min 
and washed five times for 5 min with PB. Afterwards, sections were blocked in 10 % 
normal goat serum (NGS; Abcam, Cambridge, UK) diluted in PBT buffer for 1.5 h at 4°C. 
Primary antibodies (Table 13) were diluted as indicated in PBT buffer containing 2 % 
NGS and added onto each slide (100-200 µL), keeping in a humid box overnight at 4°C. 
Next day, sections were washed five times for 5 min each with PB and subjected to 
secondary antibodies staining (Table 13) for 2 h at 4°C. Secondary antibodies were 
diluted in PBT buffer containing 2 % NGS. DAPI was diluted to 20 µg/mL in PB and added 
to sections for 10 min at room temperature. In the end, slides were fixed in Immu-Mount 
(Thermo Fisher Scientific, Waltham, MA, USA) with a coverslip. IF images were acquired 
via FluoView 1000 confocal microscopy (Olympus FluoView 1000) and quantified either 
manually by counting positive cells or by measuring staining intensity (as integrated 
density above a set threshold, given as arbitrary units (A.U.)) using ImageJ Fiji software 
(Schindelin et al., 2012). 
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2.2.2 Cell culture  
2.2.2.1 Cell culture for established PDAC cell lines 
Human PDAC cell lines (CAPAN1, CAPAN2, PANC1, and MiaPaCa2) were obtained 
from the ATCC. PT45P1 cell line was kindly provided by G. Natoli (Humanitas University, 
Malian, Italy). CAPAN1, CAPAN2, and PT45P1 were cultured in Roswell Park Memorial 
Institute (RPMI) 1640 Medium (ThermoFisher Scientific, Waltham, USA) supplemented 
with 10% fetal calf serum (FCS; BioWest, Nuaillé, France). PANC1 and MiaPaCa2 were 
cultured in Dulbecco’s modified Eagle’s Medium (DMEM; ThermoFisher Scientific, 
Waltham, USA) supplemented with 10% FCS. The primary PDAC cell line derived from 
KrasG12D; Trp53R172H; PdxCre (KPC) mice has been described previously (Patzak et al., 
2019). KPC cells were maintained in DMEM supplemented with 10% FCS and 1% non-
essential amino acids (NEAA; ThermoFisher Scientific, Waltham, USA). All cell lines were 
kept at 37 ºC and 5 % CO2. 
For thawing cells, stocks were immediately defrosted in a 37 ºC water bath and then 
mixed with 8 mL complete culture medium, followed by centrifugation at 1200 rpm for 3 
min. The cell pellet was resuspended in 10 mL culture medium and transferred into a 
culture flask. Cells were passaged at least once after thawing before conducting any 
functional experiment.  
For making cell stocks, cells pellets were resuspended in freezing medium [90 % FCS 
plus 10 % dimethyl sulfoxide (DMSO)] and aliquoted into cryotubes. Cells were stored in 
Mr. Frosty containers in a -80 ºC freezer overnight and then transferred into liquid nitrogen 
for long term storage. 
2.2.2.2 Generation of primary PDAC cells from patient-derived xenografts  
The used patient-derived xenograft (PDX) model was established by S. Hahn (Ruhr-
University Comprehensive Cancer Center, Bochum, Germany). Surgically resected 
PDAC tissues collected from patients were implanted subcutaneously in NMRI Foxn1nu/nu 
mice. Resulting xenograft tumors were isolated and re-implanted in both flanks of mice 
for at least three generations. The PDX tumors were harvested and subsequently 
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dissociated by gentleMACS dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany). 
For the isolation of primary PDX tumor cells, the human tumor dissociation kit and mouse 
cell depletion kit (Miltenyi Biotec, Bergisch Gladbach, Germany) were utilized according 
to the manufacturer’s protocol. Selected primary PDX tumor cell lines (GCDX5, GCDX57, 
and GCDX62) were cultured in type I collagen-coated dishes for several passages, and 
then transferred to normal culture vessels for further experiments. Xenografting and 
generation of PDX cell lines was performed by S.K. Singh, E. Hessmann and W. Kopp 
(Department of Gastroenterology, GI Oncology & Endocrinology, UMG, Germany). The 
study was approved by the ethics committee of the Ruhr University Bochum (permission 
no. 3534-9, 3841-10, 16-5792) and the University Medical Center Göttingen (permission 
no. 70112108). All animal experiments were performed according to the guidelines of the 
local Animal Use and Care Committees at the Ruhr University Bochum (8.87-
50.10.32.09.018) and the Central Animal-experimental Facility at the University of 
Göttingen (14/1634, 15/2057, 18/2953). 
GCDX cell lines were maintained in a 3:1 mixture of Keratinocyte-SFM (KSF) and RPMI 
media, supplemented with 2% (v/v) FCS, 1% (v/v) Penicillin-streptomycin, bovine pituitary 
extract (BPE), and epidermal growth factor (hEGF).  
2.2.2.3 Generation of lentiviral and retroviral transduced stable cell lines 
For the preparation of virion, 2 x 106 HEK-293T (clone 17) cells (ATCC, Manassas, 
Virginia, USA) were seeded in a 10 cm dish. The next day, HEK-293T cells were 
transfected with gene of interest (GOI)-containing plasmid (10.67 µg), envelope vector 
(5.33 µg) with either 8 µg of lentiviral psPAX2 or retroviral pKAT (Finer et al., 1994) 
packaging vectors using Lipofectamine 2000 (Invitrogen, USA). The cell supernatant 
containing virus was collected and filtered through 0.45 µm membrane filter (Merck 
Millipore, Billerica, USA). The virus-containing media and polybrene were then used to 
transduce target cells (Santa Cruz Biotechnology, Dallas, USA). 24 h post transduction, 
fresh culture medium was added to replace the virus-containing medium. After 72 h, cells 
were selected by 2 µg/mL puromycin (Sigma-Aldrich, St. Louis, USA) and maintained 
subsequently in 0.5-1 µg/mL culture medium. All the constructs used are listed in Table 
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6. All the transduced stable cell lines were kindly generated by K. Bojarczuk and B. 
Chapuy (Department of Hematology and Medical Oncology, UMG, Germany). 
2.2.2.4 Cell viability assay for chemosensitivity experiments 
The CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, USA) was 
performed to quantify cell viability according to the manufacturer’s instructions. For 
individual experiments, 6 x 103 cells were seeded in 96-well plates in 100 µL per well 24 
h prior to treatment. Gemcitabine, SN38 (an active Irinotecan metabolite) or oxaliplatin 
were diluted to different concentrations as indicated in the figures and applied to individual 
wells. After 72 h, plates were equilibrated to RT for 30 min. Cells were subsequently 
incubated with 30 µL CellTiter-Glo solution and kept on a shaker (400-600 rpm) for 2 min, 
and incubated in the dark for 10 min. The mixture was then transferred into a 96-well 
white plate and subjected to measurement of the luminescence via a LUmo Luminometer 
at an integration time of one second per well. 
2.2.2.5 Flow cytometry analysis 
1 x 106 cells were taken freshly for the cell surface staining of TNFα or TNFα-mCherry 
reporter gene. Firstly, cells were transferred into a 96-well plate (round bottom) at a 
concentration of 1 x 105 cells/well. Subsequently, cells were centrifuged at 300 X g for 5 
min and washed once with FACS buffer (10% knock out serum in -Ca/-Mg PBS; 
ThermoFisher Scientific, Waltham, USA). PDAC cells were either stained with primary 
antibodies or untreated control for 30 min at RT. Cells were then washed with 200 μL 
FACS buffer twice prior to flow cytometry analysis. For endogenous TNFα expression, 
488 nm laser was used to detect established PDAC cell lines (CAPAN1, CAPAN2, 
PANC1, and MiaPaCa2). For the mCherry expression, 561 nm laser was used to detect 
TNFα-mCherry overexpressing cells (TNFα-OE). Antibodies used for this study are listed 
in Table 12. 
2.2.2.6 siRNA transfection 
2.5 x 105 cells were seeded in 6-well plates (2 mL per well). The next day, culture media 
was freshly changed to 1 mL 30 min prior to transfection. For each well, transfection 
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mixture was prepared by adding 6 µL siLentFect lipid reagent (Bio-Rad, Hercules, CA, 
USA) and 6 µL of 20 µM sicJUN, siBRD4 or non-targeting siRNA to 200 µL Opti-MEM 
medium (ThermoFisher Scientific, Waltham, USA). The lipid-siRNA mixture was 
incubated at room temperature for 15 min and then added into wells. Cells were incubated 
with siRNA for 24 h, after which the medium was exchanged. Protein or RNA was 
harvested 48-72 h after transfection. siRNA sequences used for this study are listed in 
Table 8. 
2.2.2.7 Trans-well invasion assay 
16 µL type I collagen stock was diluted in 984 µL 0.1 M HCl in a microtube. The bottom 
of 8 µm porous inserts for 24-well plates were coated with 50 µL diluted collagen, which 
solidifies after 1-2 h. Matrigel (Abcam, Cambridge, UK) was thawed on ice and 50 µL 
were mixed with 10 µL medium containing 1 x 105 cells. The solution was seeded in 
coated inserts in duplicates and incubated at 37°C for 30 min. Subsequently, 250 µL 
culture medium was added to inserts and 750 μL to the wells. After 48 h, Matrigel was 
removed from the inserts with cotton swabs. Invaded cells on membranes were fixed with 
4% PFA, followed by three times washing of PBS. The membranes of inserts were 
removed and stained with 20 µg/mL DAPI for 1 min. Pictures were acquired using a 
FluoView 1000 confocal microscope and FV10-ASW software version 4.2 (Olympus, 
Shinjuku, Japan). The invaded cells were counted manually per 20X field of view (F.o.V) 
from 10 pictures per replicate. 
2.2.3 Molecular biology  
2.2.3.1 RNA extraction  
Cells were washed twice with PBS, scraped in 800 μL TRIzol (ThermoFisher Scientific, 
Waltham, USA) and collected in a 1.5 mL microtube. 200 μL chloroform were added to 
each sample, followed by vortexing and centrifugation at 13000 X g for 15 min at 4 °C. 
The aqueous phase was transferred into a new tube which allows RNA precipitation by 
incubation with 500 µL iso-propanol at room temperature for 10 min. Samples were then 
centrifuged at 13000 X g for 30 min at 4 °C and subsequently washed twice with 1 mL 
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75% ethanol. Dried pellets were ultimately dissolved in 30 μL aqua dest. and stored at -
80 ºC. 
2.2.3.2 cDNA synthesis  
RNA concentration was measured using a Nano Photometer-P330 (Intas Science 
Imaging, Göttingen, Germany). 1 μg RNA was used for cDNA synthesis using the iScript 
cDNA synthesis kit (Bio-Rad Laboratories, Hercules, USA) as per manufacturer’s 
instructions. cDNA synthesis was performed in a thermal cycler as follows: 25 ºC for 5 
min, 46 ºC for 20 min, 95 ºC for 1 min. The 20 μL reaction volume was finally diluted with 
80 μL aqua dest. 
2.2.3.3 qRT-PCR 
Quantitative real-time PCR (qRT-PCR) reaction was prepared as shown in Table 32: 
Table 32. qRT-PCR reaction volume. 
Reactions Volume per single 10µL reaction 
SYBR green mix 5 µL  
Aqua dest. 3.5 µL  
Forward primer 0.25 µL  
Reverse primer 0.25 µL  
cDNA 1 µL  
 
qRT-PCR primers used in this study are listed in Table 9. All samples were pipetted in 
triplicates and performed by StepOnePlus Real-Time PCR System (Applied Biosystems, 
Foster City, USA) with the program shown in Table 33: 
Table 33. qRT-PCR program. 
Program  Temperature  Time  Cycle number 
Initiating phase 95 ºC 10 min  
 95 ºC 15 s 40 cycles (mRNA 
qPCR) or 55 cycles 
(ChIP-qPCR) 
 60 ºC 1 min 





95 ºC 15 s  
60 ºC 1 min  
95 ºC 15 s  
 
2.2.3.4 Chromatin immunoprecipitation 
Cells were cultured in 15 cm culture dishes until they reached 80-90 % confluency and 
then fixed with 1 % formaldehyde at room temperature for 15-20 min. 1.25 M glycine (Carl 
Roth, Karlsruhe, Germany) was added for 5 min to quench the reaction. Nelson buffer 
containing protease and phosphatase inhibitors (1 mM PMSF, 1 mM NaO, 10 mM NaF, 
and 1 X cocktail cOmplete) was used to lyse the cells to release nuclei. After 
centrifugation at 12000 X g for 2 min at 4 ºC, nuclei pellet was suspended in Gomes lysis 
buffer containing 0.1 % SDS, protease and phosphatase inhibitors (1 mM PMSF, 1 mM 
NaO, 10 mM NaF, and 1 X cocktail cOmplete). The suspension was aliquoted into 
sonication tubes as 250 µL per tube prior to sonication, which was performed by 
Diagenode Biorupter-Pico with 30 seconds ON/OFF pulse for 10-15 cycles. 30 µL 
sheared chromatin was incubated with RNase A (0.75 µL from 30 mg/ml stock; 55 °C, 30 
min; Sigma-Aldrich, St. Louis, USA) and proteinase K (1 µL from 20 mg/mL stock; 65 °C, 
overnight; AppliChem, Darmstadt, Germany) and then loaded on a 1.5 % agarose gel for 
the confirmation of fragment size. Properly sheared chromatin (from 200 to 600 bp) was 
then pre-cleared by incubation with 100 µL 50 % slurry protein A agarose beads on a 
rotator for 1 h at 4 ºC. Subsequently, samples were centrifuged at 12000 X g for 2 min at 
4 ºC and the supernatant aliquoted for the gene of interest, IgG isotype control, and input. 
If not processed immediately, samples were snap-frozen and kept at -80 ºC. ChIP-grade 
primary antibodies were incubated with samples on rotator overnight at 4 ºC. Agarose 
beads were blocked in BSA (1 µg/µL) diluted in Gomes lysis buffer. The next day, the 
protein-antibody complex solution was incubated with blocked beads for 2 h at 4 ºC. 
Immune complex was washed as follow: 1 time Gomes lysis buffer, 2 times Gomes wash 
buffer, 2 times Gomes lysis buffer, and 2 times TE buffer to remove unspecific binding. 
Washed chromatin was then incubated with RNase A (0.2 µg/µL; 55 °C, 30 min; Sigma-
Aldrich, St. Louis, USA) and proteinase K (1 µL from 20 mg/mL stock; 65 °C, overnight; 
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AppliChem, Darmstadt, Germany) prior to DNA extraction. DNA was extracted by 
phenol/chloroform/isoamyl alcohol solution and washed once with 70 % ethanol. Final 
DNA was resuspended in 20-30 µL aqua dest. and stored at -20 ºC for further analysis. 
2.2.3.5 Protein sample preparation 
For the preparation of whole cell lysates, cells were washed twice with ice-cold PBS and 
lysed in WCL buffer on ice for 30 min. Lysates were then centrifuged at 12000 X g for 20 
min and supernatant was collected for Western blot analysis. 
2.2.3.6 Bradford assay 
Protein concentration/content was determined using Bradford reagent (Bio-Rad, Hercules, 
CA, USA). Briefly, BSA was diluted to different concentrations for the establishment of a 
standard curve. 1 µL of each protein sample was added to 200 µL Bradford reagent. The 
absorbance value was measured by PHOMO plate reader at 595 nm. The absorbance of 
samples was then used to calculate the protein concentration using the standard curve. 
2.2.3.7 Western blot analysis 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out 
to separate proteins with different molecular masses. Equal amount of protein (20 µg) 
was loaded on SDS-PAGE gel and electrophoresis was conducted at 100 V for 30 mins 
followed by 120 V for 1 h 40 min. The protein was transferred onto nitrocellulose (NC) 
membranes using a semi-dry blotting system (25V, 1.0 A). 10 % separation gel was used 
for the detection of the proteins more than 30 kDa. 15 % gel was used for proteins less 
than 30 kDa. Proteins on NC membrane were visualized by short incubation with Ponceau 
S solution. Subsequently, membrane was blocked with 5% (w/v) milk powder in TBST 
buffer for 1 h at room temperature, followed by incubation with primary antibodies 
overnight at 4°C. Secondary HRP-linked antibodies were incubated for 1 h at room 
temperature. All antibodies were diluted in 5 % milk powder in TBST buffer. Protein was 
detected by an Intas ChemoCam Imager using ECL substrate (Bio-Rad, Hercules, USA). 
Antibodies used for this study are listed in Table 11. 
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2.2.3.8 Proteome profiler cytokine array 
Cells were seeded in a 6-well plate in 2 mL medium and grown to 80-90 % confluency. 
48 h after a medium change the supernatant was collected and centrifuged at 5,000 X g 
for 5 min prior to cytokine detection using Proteome Profiler Human Cytokine Array Kit 
(R&D Systems, Minneapolis, USA) following the manufacturer’s instructions. 
2.2.3.9 ELISA  
Cells were seeded in a 24-well plate in 500 µL medium. 48 h after medium change the 
supernatant was collected and centrifuged at 5,000 X g for 5 min prior to detection. The 
levels of secreted human TNFα were measured by Quantikine ELISA kit (R&D Systems, 
Minneapolis, USA). For in vivo detection, blood samples were collected and centrifuged 
at 4000 X g for 10 min. Plasma of control and TNFα treated mice were measured for 
human and murine TNFα by Quantikine ELISA kit (R&D Systems, Minneapolis, USA). 
2.2.4 Next generation sequencing  
2.2.4.1 RNA-seq and data processing 
5 x 105 CAPAN1 cells were seeded in 6-well plates. The next day, cells were treated with 
either TNFα (10 ng/mL; Sigma-Aldrich, St. Louis, USA) or vehicle control for 18 h. Next, 
cells were harvested in TRIzol (Ambion, Kaufungen, Germany) for RNA isolation (three 
biological replicates). The RNA quality was checked by agarose gel electrophoresis. 
cDNA library was prepared using 500 ng of total RNA and the TruSeq RNA Library Prep 
kit (Illumina, San Diego, USA) as per manufacturer’s instructions. cDNA concentration 
was measured via Qubit dsDNA high sensitivity assay (Thermo Fisher Scientific, Waltham, 
USA). Fragment sizes were confirmed by Bioanalyzer high sensitivity DNA analysis 
(Agilent Technologies, Santa Clara, California, USA) prior to sequencing (single-end 50 
bp) on a HiSeq2000 (Illumina, San Diego, USA). Sequencing was performed at the core 
facility of NGS Integrative Genomics Unit at the UMG, Göttingen. 
For data analysis, the read-outs were quality-checked using FastQC v0.11.5 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads were mapped 
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against reference human genome hg38 by STAR v2.5.2b (Dobin et al., 2013), Next, 
aligned reads were assigned to individual genes for transcript quantification by HTSeq-
count version 0.10.0 (Anders et al., 2015). Differential expression analysis was performed 
by DESeq2 (Love et al., 2014). Genes were considered differentially expressed between 
treatments if they had an absolute log2-fold change of > 0.58 and an adjusted p-value of 
< 0.05. Principle component analysis (PCA) was determined by prcomp function in R and 
plotted by ggplot2 in R. pheatmap package in R was utilized for generating heatmaps. 
Gene set enrichment analysis (GSEA) was performed using R package clusterProfiler 
(Yu et al., 2012). Bioinformatic analysis was performed by X. Li (Developmental Biology, 
University of Göttingen, Germany). 
2.2.4.2 ChIP-seq library preparation and data processing 
10-15 x 106 cells were cross-linked in 1% PFA (PBS-diluted) for 10 min at room 
temperature. Subsequently, cells were quenched in ice-cold glycine (0.125 M) for 5 min. 
The preparation of ChIP materials was followed by the protocol from Ford et al. (Ford et 
al., 2014). A Bioruptor sonicator was utilized to generate a size of 300-500 bp DNA 
fragments (https://ethanomics.files.wordpress.com/2012/01/chip_covaris4.pdf). For the 
immunoprecipitation, antibodies used are listed in Table 14. Immunoprecipitated DNA 
was purified using the ChIP DNA Clean & Concentrator kit (Zymo Research Europe, 
Freiburg, Baden-Württemberg, Germany), following the manufacture’s instruction. Next-
generation sequencing (single-end) was conducted on a HiSeq4000 platform (Illumina, 
San Diego, USA) to obtain at least 20 million reads per sample. Raw sequencing reads 
(~100 bp) were mapped to the reference human genome (hg19) using BWA (Li and 
Durbin, 2010). Peak calling was performed by MACS2 (Zhang et al., 2008) to identify 
signal enrichment over input. Next, genes were assigned to peaks through GREAT 
(http://great.stanford.edu/public/html/). ChIP-seq analysis was performed by T. 
Georgomanolis (Cologne Center for Genomics, University of Cologne, Germany). 
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2.2.5 Tissue microarray (TMA) staining and analysis 
Human PDAC tissue microarray (TMA) slides were obtained from the Departments of 
Pathology as well as General, Visceral and Pediatric Surgery of the University Medical 
Center Göttingen following the ethical regulations of the institute (70112108). In total, 46 
matched PDAC patient samples were evaluated, with one to three cores per patient. IF 
staining, TMA evaluation, and data acquisition were performed as described above. 
2.2.6 Publicly available PDAC microarray data analysis 
For patient microarray expression analysis, data from Puleo et al. (Puleo et al., 2018) was 
downloaded from the ArrayExpress database (E-MTAB-6134). For genes associated with 
multiple probes, the probe with the highest average expression across all patients were 
used for the analysis. For gene set overrepresentation analysis in squamous and 
pancreatic progenitor PDAC patient tumors (Bailey et al., 2016), the differential 
expression was performed on the R2 platform (https://hgserver1.amc.nl/cgi-
bin/r2/main.cgi) using the default parameters and enrichment analysis conducted using 
clusterProfiler as described above. Publicly available patient data analysis was performed 
by Lukas Klein (Department of Gastroenterology, GI Oncology & Endocrinology, 
University Medical Center Göttingen, Germany) 
2.2.7 Statistical analysis 
GraphPad Prism version 8.0.2 was used for statistical analysis (GraphPad Software, San 
Diego, USA). Mann-Whitney test, or unpaired Student’s t-test was performed for the 
comparison of two groups. Log-rank test was applied for survival data. For gene 
expression correlation of published microarray data, the Pearson’s correlation coefficient 
with a two-tailed P value was calculated. Results were considered significant with a P 




3 Results  
3.1 High level of TNFα is associated with BL phenotype in PDAC 
In order to investigate the role of TNFα in PDAC progression, we first examined whether 
there was any correlation between TNFα expression and a certain tumor phenotypic 
identity. Therefore, we utilized a genetically engineered KrasG12D;p53R172H;PdxCre (KPC) 
mouse model, which is widely used in PDAC studies as it recapitulates human pancreatic 
carcinogenesis (Hingorani et al., 2005). KPC tumor sections were subjected to H&E 
staining. KPC tumors were highly heterogeneous and contained both well-to-moderately 
differentiated (W/M) and poorly differentiated tumor contents. As shown in Figure 6A, G1 
and G2 tumors presented W/M tumor features, with glandular, duct-like structures, 
whereas G3 and G4 tumors were lacking cellular differentiation, forming extremely poorly 
differentiated histological features. We then probed TNFα and cytokeratin-19 (CK19) on 
these W/M (G1-G2) and poorly differentiated (G3-G4) KPC tumor tissues. CK19 is a 
surrogate marker for tumor cells. Notably, TNFα was found to be highly expressed in 
poorly differentiated tumors (G3-G4) when compared with W/M (G1-G2) differentiated 
tumors (Figure 6B), indicating an association between TNFα and the poorly differentiated 
phenotypic state. 
To further evaluate the tumor phenotype-dependent expression of TNFα, human CLA 
and BL orthotopic mouse models were generated to investigate whether TNFα was highly 
expressed in BL tumors, which are associated with poorly differentiated tumors. To this 
end, immunodeficient mice were selected to allow human PDAC cells (CLA and BL) to 
grow inside the pancreas. The established CLA (i.e. CAPAN1 and CAPAN2) and BL (i.e. 
PANC1 and MiaPaCa2) cell lines were orthotopically transplanted into the pancreas of 
immunodeficient mice NMRI-Foxn1nu/nu. Notably, the CLA subtype-derived tumors 
maintained glandular structures and formed well differentiated tumors, and the liver 
tissues did not form any visible metastases. In comparison, as expected, the BL tumors 
formed poorly differentiated tumors and liver metastases (Figure 6C). Double 




and BL orthotopic tumors. In line with the observation in KPC mice, TNFα was found to 
be highly expressed in the BL tumors compared to CLA tumors (Figure 6D). 
 
Figure 6. Phenotype-dependent expression of TNFα in PDAC. (A) Representative H&E 
images of graded (G1 to G4) KrasG12D;p53R172H;PdxCre (KPC) tumor tissues. Scale bar: 20 µm. 
(B) Immunofluorescence (IF) staining of TNFα (red) and cytokeratin 19 (CK19) in well-to-
moderately differentiated (W/M) as well as poorly differentiated tumors of KPC mice. Scale bar: 
50 µm. n=5 in W/M; n=5 in poorly. (C) Representative images of H&E staining in pancreatic tumors 
and liver tissues derived from orthotopically implanted classical (CLA) CAPAN1 as well as basal-
like (BL) MiaPaCa2 mouse models. Scale bar: 20 µm. (D) IF staining of TNFα (red) and CK19 





To further validate whether high levels of TNFα determines subtype-specificity, we used 
histologically characterized W/M and poorly differentiated resected PDAC patient tumors. 
Notably, we observed high TNFα levels particularly in the poorly differentiated tumors 
compared to W/M PDAC (Figure 7A and 7B). Collectively, these data indicate that high 
levels of TNFα are associated with highly aggressive BL phenotypic state. 
 
Figure 7. TNFα is highly expressed in poorly differentiated PDAC patient tumors. (A) 
representative tile scan images of IF staining of TNFα in W/M and poorly differentiated PDAC 
patient tumors. I-III show higher magnification images. Scale bar: whole section (top): 2 mm; 
higher magnification images (bottom): 10 µm. (B) Quantification of TNFα intensity in (A). Scatter 
plots show values in arbitrary units (AU) of each patient, as well as means ± s.d. as bar graphs. 
Mann-Whitney test was used for statistical analysis. n=5 in W/M; n=6 in poorly. 
 
3.2 TNFα promotes CLA to BL phenotypic switch in PDAC 
3.2.1 TNFα promotes poorly differentiated phenotypic state in vivo  
Next, we sought to investigate whether TNFα promotes tumor aggressiveness in PDAC. 
Therefore, CLA (i.e. CAPAN1) subtype cells were orthotopically implanted in mice and 




mice were implanted with CAPAN1 cells into the pancreas. Three weeks after 
transplantation, as it approached the time that tumor started to form, 3D ultrasound was 
used weekly to evaluate the tumor growth until mice developed a decently sized tumor 
(approx. 6 mm in diameter) (Figure 8B). Mice were administrated TNFα or vehicle control 
intraperitoneally (i.p.) three times per week. At the endpoint (three weeks of TNFα 
treatment), mice were sacrificed for tissue isolation. 
 
Figure 8. Schematic of orthotopically implanted PDAC cells into the pancreas. (A) An 
illustration of the experimental design. 10-weeks old male immunodeficient NMRI-Foxn1nu/nu mice 
were orthotopically implanted with 1 x 106 CLA cell line CAPAN1 into the pancreas. Three weeks 
after transplantation, (B) ultrasound was performed weekly to evaluate the tumor growth. 
Treatment began when the tumor diameter reaches approx. 6 mm. TNFα (0.4 mg/kg body weight) 
was injected intraperitoneally (i.p.) three times a week, using aqua dest. as control. Mice were 
sacrificed after three weeks of treatment. Tissues were collected including entire pancreatic tumor, 
spleen, liver, lung, and blood samples. 
 
Next, tumor tissues harvested from vehicle control (VC) and TNFα-treated mice were 
subjected to H&E staining. In order to have an overview of the tumor histology, whole 




selected tumor areas at a higher magnification are shown in Figure 9A. In general, control 
tumors exhibited a W/M differentiated phenotype that fully recapitulates the CLA PDAC 
subtype identity. However, the proportion of poorly differentiated tumor area significantly 
increased in TNFα-treated mice, which is a sign for the BL subtype, as quantified in 
Figure 9B. Duct-like structures were prominent in the VC tumors compared to more 
separated and irregular structures in the TNFα-treated tumors, suggesting that TNFα 
switched CLA to the highly aggressive BL phenotypic state. 
 
Figure 9. TNFα promotes W/M to poorly differentiated phenotype. (A) Representative tile 
scan images of H&E staining in pancreatic tumor tissues from vehicle control (VC) and TNFα-
treated orthotopically implanted mice (CAPAN1). I-III show higher magnification images. Scale 
bar: whole section (top): 2 mm; representative images (middle): 200 µm; higher magnification 
images (bottom): 10 µm. (B) Scatter plots show quantification of poorly differentiated tumor area 
as a percentage of total tumor area in VC and TNFα-treated mice, as well as means ± s.d. as bar 





To further validate our observations, IF staining was performed for Keratin-81 (KRT81) 
and amylase in the tumors developed from VC and TNFα-treated mice. Of note, KRT81 
is an established clinical marker that is specifically expressed in the BL tumors (Noll et 
al., 2016). Additionally, PDAC patients showing high levels of KRT81 have a lower 
survival rate (Noll et al., 2016). Amylase was used to stain for normal pancreatic acinar 
cells, which allowed us to distinguish tumor cells from normal tissue. We observed a 
significant induction of KRT81 expression in the tumor core as well as peritumoral regions 
(amylase+) following TNFα treatment (Figure 10), consistent with the tumor histology.  
Interestingly, except for the induced BL invasive phenotype, abundant infiltration of CD45+ 
immune cells were found in the TNFα-treated tumors. In contrast, VC tumors barely have 
CD45+ cells present (Figure 11). Collectively, these data suggest that TNFα promotes a 
poorly differentiated/BL phenotype and immune cell infiltration in PDAC. 
 
Figure 10. TNFα treatment leads to high level of of KRT81 in vivo. (A) Representative IF 
images of KRT81 (red) and amylase (green) in orthotopic CAPAN1 VC and TNFα treated 
pancreatic tumor tissues. scale bar: 50 µm. (B) Quantification of KRT81 in (A). Scatter plots show 
values in arbitrary units (AU) as an average per animal, as well as means ± s.d. as bar graphs. 
10 images were evaluated per animal. Mann-Whitney test was used for statistical analysis. n=7 






Figure 11. TNFα treatment induces CD45+ immune cell infiltration. (A) Representative IF 
images of CD45 (green) in orthotopic CAPAN1 VC and TNFα treated tumor tissues. Scale bar: 
50 µm. (B) Quantification of CD45+ cells in (A). Scatter plots show average values per animal of 
counts per field of view as well as means ± s.d. as bar graphs. 10 images per animal were 
evaluated. Mann-Whitney test was used for statistical analysis. n=5 in VC; n=6 in TNFα. 
 
3.2.2 TNFα promotes invasive behavior of CLA PDAC cells 
To understand the mechanism underlying the observed phenotypic switch in vivo, we 
performed a 3D-transwell invasion assay in CLA cells following TNFα treatment. The 
number of invading cells was significantly induced in presence of TNFα in both CLA cell 
lines, i.e. CAPAN1 and CAPAN2 (Figure 12A and 12B). Additionally, the increased 
invasive capacity was associated with an induction of EMT marker ZEB1, concomitant 
with a reduction of differentiation marker KLF5. The most prominent effect was seen after 





Figure 12. TNFα increases the invasive capacity of CLA cells. (A) 3D-transwell invasion assay 
of CLA cell lines (CAPAN1 and CAPAN2) treated with TNFα (10 ng/mL), or aqua dest. as vehicle 
control (VC). Representative images of DAPI-stained invaded CAPAN1 and CAPAN2 cells. Scale 
bar: 50 µm. (B) Quantification of invaded cells as shown in (A). Scatter plots show average values 
per technical replicate of counts per F.o.V. as well as means ± s.d. as bar graphs. Mann-Whitney 
test was used to determine the statistical significance. n=3. (C) Western blot analysis of ZEB1, 
KLF5 upon TNFα or VC treatment for 24 h and 48 h in CLA cells CAPAN1 and CAPAN2. Actin 
was used as a loading control. Representative of three independent experiments. 
 
3.2.3 TNFα induces CLA to BL subtype switch by transcriptional 
reprogramming of lineage-specific genes 
To gain further insight into the molecular mechanisms underlying the TNFα-mediated 




TNFα or vehicle control. Gene set enrichment analysis (GSEA) revealed a significant 
enrichment of EMT and inflammatory response hallmarks in TNFα-treated samples 
(Figure 13A), consistent with our previous observations of TNFα-treated orthotopic 
tumors as well as in vitro experiments (Figure 9, Figure 11, and Figure 12). Additionally, 
gene sets linked to the invasive PDAC subtype such as ‘KRAS signaling down’ and 
‘Myogenesis’ (Miyabayashi et al., 2020) were also found to be enriched in the TNFα-
treated samples (Figure 13B), whereas gene sets involved in ‘Fatty acid metabolism’, 
‘Adipogenesis’, and ‘Myc targets V1’ were enriched in control samples (Figure 13B). To 
determine whether TNFα-altered gene signatures associated with a particular PDAC 
subtype, we utilized the publicly available CLA-related gene sets, as previously reported 
(Maurer et al., 2019). We found that TNFα treatment led to a reduction in the expression 
of most CLA-specific genes (Figure 13C). The genes that were upregulated coinciding 
with a known BL signature, as well as downregulated genes coinciding with CLA were 
shown in volcano plot (Figure 13D). Taken together, these data suggest that TNFα 








Figure 13. TNFα induced PDAC subtype-specific gene regulatory network. (A) Enrichment 
plots from gene set enrichment analysis (GSEA) in 18h TNFα-treated (10 ng/mL) versus vehicle 
control (VC) samples in CLA CAPAN1 cells. Normalized enrichment scores (NES) and q-values 
are indicated. (B) Normalized enrichment scores of selected Hallmark gene sets from the 
Molecular Signature Database in CAPAN1 cells with TNFα versus VC treatment. (C) Heatmap 
displays expression of CLA-associated genes as defined by Maurer et al. (Maurer et al., 2019) in 




analysis. Upregulated genes coinciding with known BL markers and downregulated genes 
coinciding with CLA are plotted in red. 
 
3.3 Molecular subtypes of PDAC determine distinct tumor 
microenvironment  
3.3.1 BL-specific immune cells are source of TNFα in PDAC TME 
Based on the earlier observation that TNFα was preferably expressed in the poorly 
differentiated tumors (chapter 3.1), we initially hypothesized that the BL PDAC cells might 
be the source of TNFα. Thus, TNFα expression was examined in CLA and BL cells by 
flow cytometry. Despite the pivotal role of TNFα in vivo, we did not find significant levels 
of TNFα in either CLA (i.e. CAPAN1 and CAPAN2) or BL cells (i.e. PANC1 and MiaPaCa2) 
(Figure 14A). For further validation, human-specific TNFα ELISA was performed in the 
supernatant from these cells. Consistently, TNFα expression was not detected in all the 
cell lines (Figure 14B). 
 
Figure 14. TNFα is not produced by PDAC cell lines. (A) Flow cytometry analysis was 




MiaPaCa2, using anti-TNFα antibody, without any staining (UN), and isotype control (IgG1). 
Counts of gated cells are shown against fluorescence intensity, which is linked to TNFα 
expression. n=3. (B) Concentrations of TNFα in cultured CLA CAPAN1 and CAPAN2 as well as 
BL PANC1 and MiaPaCa2 cells as measured by human-specific ELISA. n=2. 
 
Given that none of the PDAC cell lines produced TNFα, we considered that inflammatory 
TME might be the source of TNFα production in PDAC tumors. Thus, human- and murine-
specific ELISA in was carried out in the plasma-derived from the above-mentioned CLA 
and BL orthotopically transplanted mice (Figure 6). Notably, human TNFα secretion was 
not detected in either CLA or BL plasma samples (Figure 15A). Strikingly, murine TNFα 
was detected only in BL plasma (Figure 15B). Additionally, TNFα expression was 
measured in the previously mentioned TNFα-treated CLA mouse model (Figure 8). 
Human TNFα was able to be detected in the TNFα-treated mice as expected (Figure 
15C), since human recombinant TNFα was administrated in these mice. Besides, we 
noted that murine TNFα could be detected as well in the TNFα treated mice (Figure 15D).  
Together, human TNFα was not detectable in the PDAC cell lines as well as in the plasma 
from CLA and BL tumor bearing mice. However, murine TNFα was detectable in the BL 
and induced the TNFα-treated CLA plasma samples, suggesting that TNFα originated 
from the host inflammatory TME. 
 
Figure 15. Host immune inflammatory tumor microenvironment produces TNFα in the BL 
PDAC subtype. (A and B) Human-specific (A) and murine-specific (B) TNFα ELISA in plasma 




values of each animal as well as means ± s.d. as bar graphs. Mann-Whitney test was used to 
determine the statistical significance. (A) n=12. (B) n=5. (C and D) Human-specific (C) and 
murine-specific (D) TNFα ELISA in plasma samples isolated from VC and TNFα-treated CLA mice. 
Scatter plots show values of each animal as well as means ± s.d. as bar graphs. Mann-Whitney 
test was used to determine the statistical significance. (C) VC, n=5; TNFα, n=5. (D) VC, n=6, 
TNFα, n=8. 
 
3.3.2 Subtype-dependent immune cell infiltration  
To find out whether immune cells in the inflammatory TME were the source of TNFα, we 
performed IF staining of CD45 in the CLA and BL orthotopic tumors. Notably, CD45+ cells 
were highly present in the BL orthotopic tumors compared to the CLA ones (Figure 16A). 
Since macrophages are known to be abundant in the PDAC TME and associated with 
poor survival (Bailey et al., 2016; Hessmann et al., 2020; Puleo et al., 2018), we sought 
to further examine the expression of the macrophage marker CD68 in these tumor tissues 
as well as the TNFα-treated tumors where an induction of CD45+ cells was seen (Figure 
11). Notably, BL orthotopic tumors showed higher recruitment of CD68+ cells compared 
to CLA orthotopic tumors (Figure 16B). Similarly, CD68+ cells were found to be strongly 
induced upon TNFα treatment compared to VC (Figure 16C). Since these CD45+/CD68+ 
cells and TNFα are both more prominent in the BL tumors, indicating that TNFα is most 





Figure 16. CD45+ and CD68+ cells are highly infiltrated in the BL orthotopic tumors. (A) 
Representative IF staining of CD45 (green) in CLA (CAPAN1 and CAPAN2) and BL (PANC1 and 
MiaPaCa2) orthotopic tumors. Scale bar: 50 µm. n=5 in CLA; n=5 in BL. (B) IF analysis of CD68 
(red) in CLA (CAPAN1) and BL (MiaPaCa2) orthotopic tumors. n=5 in CLA; n=5 in BL. (C) 
representative IF images of CD68 (red) in VC and TNFα-treated CLA CAPAN1 orthotopic tumors. 
Scale bar: 50 µm. n=6 in VC; n=6 in TNFα-treated. 
 
3.3.3 Subtype-specific intrinsic factors determine immune cell recruitment 
To understand the mechanism of how immune cells were recruited into the BL TME and 
its potential mediators, we first compared the cytokine expression profile between CLA 
and BL cell lines by utilizing publicly available RNA-seq data (GSE64560). Several 
cytokines were found to be upregulated in the BL cells, including CCL2, which is known 
to be associated with macrophages recruitment (Nagarsheth et al., 2017) (Figure 17A). 
Next, we used an unbiased approach via the Proteome Profiler Human Cytokine Array 
Kit to detect cytokine production in human CLA and BL PDAC cell lines. Consistently, 
CCL2 was observed to be highly upregulated in BL PANC1 and PT45P1 cell lines 




As CCL2 expression correlated with the BL subtype in PDAC cell lines, we next sought 
to elucidate whether there was a correlation between CCL2 and subtype identity in PDAC 
patient tumors. Hence, we analyzed CCL2 status in the Bailey-defined pancreatic 
progenitor (or CLA) and squamous (or BL) subtypes (Bailey et al., 2016). In line with the 
association of CCL2 to the BL PDAC cells, CCL2 was found to be highly enriched in the 
squamous (i.e. BL) subtype compared to pancreatic progenitor (i.e. CLA) tumors (Figure 
17C). Next, the association of CCL2 and CD68+ macrophages was verified in a publicly 
available microarray dataset of PDAC patient tumors (Puleo et al., 2018). We found that 
CCL2 correlated positively with CD68 (Figure 17D). Taken together, these results 




Figure 17. CCL2 is linked to BL PDAC subtype and associates with CD68+ macrophages. 




(PANC1 and MiaPaCa2) PDAC cell lines. Publicly available RNA sequencing data (GSE64560; 
Diaferia et al., 2016) was reanalyzed by F. Wegwitz (Department of Gynecology and Obstetrics, 
UMG). Cytokines significantly upregulated in BL cells compared to CLA cells are highlighted. (B) 
Expression of cytokines detected by Proteome Profiler Human Cytokine Array Kit. CLA CAPAN1 
and CAPAN2 as well as BL cells PANC1 and PT45P1. Unlabeled black spots with lines indicate 
for positive control. (C) Expression of CCL2 in well-defined pancreatic progenitor (n=30) and 
squamous (n=25) patients (Bailey et al., 2016). Data was retrieved by L. Klein (Department of 
Gastroenterology, GI Oncology & Endocrinology, UMG) using R2, an online platform for genomic 
dataset analysis (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). Mann-Whitney test was used to 
determine the statistical significance. (D) Correlation analysis of CCL2 and CD68 in 309 PDAC 
patient tumors (Puleo et al., 2018). Data was obtained from the ArrayExpress database (E-MTAB-
6134). RMA normalized probe intensity were plotted. A linear regression with 95 % CI is shown 
in orange.  
 
3.4 Distinct AP1 transcription factors determine PDAC subtype 
identity  
3.4.1 Mutually exclusive expression of JUNB/AP1 and cJUN/AP1 in PDAC 
To elucidate the mechanism of the observed cytokine upregulation, we analyzed publicly 
available patient microarray data (Puleo et al., 2018), and found a significant enrichment 
of the TNFα signaling pathway and inflammatory AP1 signaling exclusively in BL patients 
(Figure 18A). Therefore, we speculated that there might be a relevance of the AP1 
pathway to the observed inflammatory BL phenotype. Hence, we examined the 
expression of JUN/AP-1 family transcription factors (TFs) in CLA and BL cell lines. 
Strikingly, JUNB was found to be highly enriched in CLA cell lines, whereas cJUN was 
restricted into BL cells (Figure 18B). This data was further confirmed by IF staining of 
JUNB and cJUN in CLA and BL orthotopic tumors. Figure 18C shows high level of JUNB 
in CLA tumors, while cJUN was enriched in BL tumors. Next, we sought to examine 
whether the exclusivity of JUNB and cJUN was also reflected in patient tumors. Thus, we 
performed double IF staining of cJUN or JUNB together with E cadherin (ECAD) in tissue 




and highly expressed in the CLA subtype. Of note, cJUN was abundant in the area where 
ECAD was negative. Conversely, JUNB was highly co-localized with ECAD+ cells in the 
differentiated areas, whereas cJUN was absent (Figure 18D, 18E, and 18F). Collectively, 
our results show that JUNB is highly expressed in the CLA well-differentiated 
compartment, while cJUN is enriched in BL tumors. 
 
 





Figure 18. Subtype-restricted AP1 transcriptional program in PDAC. (A) Bar graph shows 
the normalized enrichment score and adjusted P values of selected pathways in CLA and BL 
subtypes based on RNA microarray analysis of 309 PDAC patients (Puleo et al., 2018). (B) 
Western blot analysis of JUN/AP1 family (cJUN, JUNB and JUND), and ECAD in CLA (CAPAN1 
and CAPAN2) and BL (PANC1 and MiaPaCa2) PDAC cells. Actin was used as a loading control. 
Representative of three independent experiments. (C) Representative IF images of cJUN and 
JUNB staining in CLA and BL orthotopic tumors. Scale bar: 50 µm. (D) Representative H&E (left 
panel) and IF staining of cJUN/ECAD (middle panel) as well as JUNB/ECAD (right panel) in tissue 
microarray (TMA) spots of 46 PDAC patients, with identical patients in each row. Scale bar: 100 
µm. (E) Number of JUNB+/ECAD+ as well as cJUN+/ECAD+ cells in TMA described in (D). Scatter 
plot shows average value per patient of all evaluated TMA spots (1-3 per patient), with means ± 
s.d. as bar graphs. Mann-Whitney test was used to determine the statistical significance n=46. (F) 
Representative IF images of cJUN/ECAD and JUNB/ECAD in moderately differentiated area as 
well as poorly differentiated primary PDAC tissues. Scale bar: 50 µm. 
 
3.4.2 Differential genome binding profile of CLA-JUNB and BL-cJUN 
Since JUNB and cJUN were found to be restricted in the specific PDAC subtype, we 
sought to explore the underlying molecular mechanism and whether they contributed to 
PDAC subtype identity. Thus, chromatin immunoprecipitation followed by sequencing 
(ChIP-seq) for JUNB and cJUN was carried out in CLA and BL cells, respectively. The 
genome binding profiles of JUNB and cJUN were clearly separated by principal 




by the differential binding profile (Figure 19B). To specify the potential role of cJUN and 
JUNB in PDAC, the genes linked to regions which were JUNB bound and gained 
openness as identified by assay for transposase-accessible chromatin followed by 
sequencing (ATAC-seq) (data not shown) in the CLA (CAPAN1) cells over the BL 
(PANC1) cells were used for Gene Ontology analysis (GO). Similarly, the genes bound 
by cJUN and gained openness in the BL PANC1 over the CLA CAPAN1 were selected. 
This analysis revealed that CAPAN1/JUNB-specific genes were involved in lipid 
biosynthesis, cell-cell adhesion regulation, and epithelial cell differentiation (Figure 19C). 
However, PANC1/cJUN-specific genes were correlated with vasculature development, 
leukocyte migration, and cytokine production (Figure 19D). These data suggest that 





Figure 19. Differential genome binding profile of cJUN and JUNB. (A) Principal component 
analysis (PCA) of JUNB and cJUN ChIP-seq profiles from CLA (CAPAN1) and BL (PANC1) cell 
lines. Two biological repeats were included for each cell line. (B) Heatmap of differential binding 
profile of ChIP-seq data of JUNB and cJUN in the CLA (CAPAN1) and BL (PANC1) cells. (C and 
D) Heatmaps of JUNB- or cJUN-occupied regions intersected with ATAC-seq peaks in CAPAN1 
(E) and PANC1 (F) respectively. Bar plots show gene ontology (GO) terms enriched for the genes 
assigned to each set of peaks. 
 
In line with the GO analysis, JUNB specifically occupies the promoter and enhancer 
regions of CDH1 (encodes the ECAD protein). Accordingly, high occupancy of H3K27ac 




at the same loci, but not in BL PANC1 cells (Figure 20A). Conversely, cJUN bound the 
VIM promoter and enhancer loci, accompanied by occupancy of H3K27ac specifically in 
BL PANC1 cells (Figure 20B). These data suggest the positive regulation of the epithelial 
marker CDH1 by JUNB, as well as the mesenchymal regulator VIM by cJUN. ChIP-qPCR 
validated that JUNB indeed bound on the promoter and one of the enhancer regions on 
CDH1 with strong H3K27ac (Figure 20C and 20D), while cJUN occupied both promoter 
and enhancer regions of VIM, associated with H3K27ac occupancy (Figure 20E and 20F). 
These data indicate that JUNB might control cell differentiation via regulation of CDH1, 
on the other hand, cJUN may support the BL phenotype through VIM. 
 
Figure 20. JUNB occupies CDH1 active promoter and enhancer and loci whereas cJUN 
binds on VIM. Coverage plots of ChIP-seq for JUNB in CLA CAPAN1 cells, as well as H3K27ac 
in CLA CAPAN2 and BL PANC1 cells at CDH1 locus. For H3K27ac ChIP-seq data, publicly 
available dataset was utilized (Diaferia et al., 2016). Enhancer (En) and promoter regions (Pro) 
are indicated. (B) Coverage plots of ChIP-seq for cJUN in BL PANC1 cells, as well as H3K27ac 
in CLA CAPAN2 and BL PANC1 cells at the VIM locus. Enhancer (En) and promoter regions (Pro) 
are highlighted. (C and D) qRT-PCR analysis following ChIP of JUNB (C) and H3K27ac (D) on 
CDH1 promoter and enhancer regions indicated in (A). n=3. (E, F) qRT-PCR analysis following 
ChIP of cJUN (E) and H3K27ac (F) on VIM promoter and enhancer regions indicated in (B). n=3. 




3.4.3 cJUN overexpression induces invasiveness of CLA PDAC cells 
To explore the functional significance of cJUN in driving a PDAC BL subtype identity, we 
established retrovirally transduced CLA cells with constitutive cJUN overexpression. 
Figure 21A confirmed that cJUN was successfully overexpressed in the CLA CAPAN1 
cells. Notably, cJUN overexpression led to a dramatic morphological change from well-
clustered islands towards a more spindle-like shape (Figure 21B). 3D-transwell invasion 
assay was conducted to compare the invasiveness between CAPAN1 empty vector (EV) 
and cJUN overexpressing (cJUN-OE) cells. Interestingly, the number of invading cells 
was significantly induced following cJUN overexpression (Figure 21C and 21D), 
suggesting that cJUN promotes an invasive behavior of PDAC cells. 
 
Figure 21. cJUN induces the invasive potential of CLA PDAC cells. (A) CLA CAPAN1 cells 
were transduced with either an empty vector (EV) or a stable cJUN overexpression (cJUN-OE) 
construct. Western blot analysis was performed to confirm the efficiency of cJUN overexpression. 




field images of (A). (C) 3D-transwell invasion assay of CAPAN1-EV and CAPAN1-cJUN-OE cells. 
Representative images show DAPI staining of invaded cells. Scale bar: 100 µm. (D) Quantification 
of invaded cells of (C). Scatter plot shows average values of count per field of view per individual 
technical replicate, as well as means ± s.d. as bar graphs. Mann-Whitney test was used to 
determine the statistical significance. n=3. 
 
Since BL subtype is in general more resistant to chemotherapy treatment, we sought to 
investigate whether cJUN-OE cells lose sensitivity to chemotherapies. Cell viability of EV 
and cJUN-OE cells was examined upon gemcitabine, oxaliplatin, and SN38 treatment 
across a wide range of concentrations as indicated in Figure 22. cJUN-OE cells showed 
a decreased sensitivity to gemcitabine with IC50 values of 14.6 nM compared to EV of 
10.92 nM (Figure 22A). A similar effect was seen following the treatment with oxaliplatin 
(cJUN-OE IC50 = 1458 nM vs EV IC50= 744.5 nM) (Figure 22B) as well as the active 
irinotecan metabolite SN38 (cJUN-OE IC50 = 4.86 nM vs EV IC50= 1.63 nM) (Figure 22C). 
These data suggest that cJUN contributes to chemoresistance in PDAC cell lines. 
 
 
Figure 22. cJUN overexpression contributes to resistance to chemotherapeutics. CAPAN1-
EV and cJUN-OE cells were seeded in 96-well plates and treated with gemcitabine, oxaliplatin, 
and SN38 at different concentrations indicated in the figure for 72 h. CellTiter-Glo was utilized to 
examine the cell viability. Dose response curves show cell viability of EV (black) and cJUN-OE 






3.4.4 cJUN-CCL2 regulation in BL PDAC cells 
Since the BL subtype has high levels of CCL2 as well as cJUN/AP1, which is known as 
an inflammatory transcriptional factor, we hypothesized that cJUN may regulate CCL2 to 
recruit macrophages. Thus, we took advantage of our cJUN ChIP-seq data in BL PANC1 
cells and visualized ChIP-seq tracks on Integrative Genomics Viewer (IGV). A significant 
enrichment of cJUN on both promoter and enhancer regions of CCL2 could be observed 
(Figure 23A), indicating that cJUN binds on the CCL2 gene in PDAC. For further 
validation, we performed individual ChIP-qPCR analysis for cJUN and H3K27ac in 
PANC1 cells with primers designed on these regions, as indicated in Figure 23A. 
Consistently, we found a significant occupancy of cJUN on the CCL2 promoter as well as 
enhancer accompanied with strong H3K27ac (Figure 23B and 23C), suggesting that 
cJUN might positively regulate CCL2 expression.  
 
Figure 23. cJUN occupies active promoter and enhancer regions of CCL2 in BL cells. (A) 
Coverage plots of ChIP-seq for cJUN and H3K27ac, as well as RNA-seq in BL PANC1 cells at 
CCL2 locus. For H3K27ac ChIP-seq and RNA-seq data in PANC1 cells, a publicly available 
dataset was utilized (Diaferia et al., 2016). Enhancer (En) and promoter regions (Pro) are 
highlighted. (B and C) qRT-PCR analysis following ChIP of cJUN (B) and H3K27ac (C) on CCL2 
promoter and enhancer regions indicated in (A) n=2. 
 
3.4.5 Loss of cJUN leads to reduction of CCL2 
To validate the regulation of cJUN on CCL2, we subjected BL PANC1 cells to cJUN-




siRNA #1 showed higher knockdown efficiency for cJUN. Therefore, it was used in all 
following experiments (Figure 24A). qRT-PCR confirmed siRNA-mediated knockdown 
on mRNA level. We observed that CCL2 mRNA expression was significantly decreased 
upon cJUN silencing (Figure 24B). cJUN-dependent expression of CCL2 was further 
validated at the protein level by Western blot analysis using the established BL cell lines 
PANC1 and PT45P1 (Figure 24C and 24D). To test whether this effect was reproducible 
in the cells isolated from patient-derived xenografts (PDX), cJUN-high cell lines GCDX5 
and GCDX57 were utilized for cJUN silencing. Consistently, CCL2 was considerably 
reduced following loss of cJUN (Figure 24E and 24F). These data strongly suggest that 
cJUN positively regulates CCL2 in BL PDAC cells. 
 
Figure 24. Effect of cJUN depletion on CCL2. (A) BL PANC1 cells were transfected with either 
siCtrl or different sicJUN sequences for 48 h. Cell lysates were subjected to Western blot analysis 
to test the efficiency of cJUN knockdown. Representative of three independent experiments. (B) 
qPCR analysis was performed for cJUN and CCL2 in BL PANC1 cells upon 48 h transfection of 
either siCtrl or sicJUN. Bar graphs show means ± s.d. Unpaired student’s t-test was used for 
statistical significance. n=3. (C-F) Western blot analysis of cJUN and CCL2 following cJUN 




patient-derived xenograft GCDX5 (E), and GCDX57 (F). Actin was used as loading control. 
Representative of three independent experiments. 
 
3.4.6 TNFα upregulates cJUN and CCL2 expression 
It is evident that TNFα is secreted from the TME and contributes to tumor progression as 
well as maintenance of the BL phenotypic state. Thus, we reasoned that TNFα might 
activate the inflammatory program in tumor cells to constitutively produce cytokines such 
as CCL2, in turn forming a positive loop for the recruitment of immune cells. To validate 
our hypothesis, we treated CLA (CAPAN1 and CAPAN2) as well as PDX-derived 
(GCDX62) cell lines with TNFα (10ng/µL) in a time dependent manner, as shown in 
Figure 25. Following the treatment with TNFα, expressions of cJUN as well as CCL2 
were markedly induced, with robust effects seen at 8 h treatment (Figure 25).  
 
Figure 25. Exogenous TNFα treatment induces expression of cJUN and CCL2 in CLA cell 
lines. Western blot analysis of cJUN and CCL2 following TNFα treatment (10 ng/mL) for 3 h, 6 h, 
and 8 h in CAPAN1, CAPAN2, and GCDX62. Actin was used as loading control. Representative 
of three independent experiments. 
 
For further validation, we engineered CLA PDAC cell lines to stably overexpress TNFα. 
Cells were transduced with either empty vector (EV) or lentiviral construct which carries 
a TNFα-mCherry insert. The expression of TNFα in these cells was confirmed by flow 
cytometry analysis (Figure 26A). CAPAN1- and CAPAN2-TNFα-OE cell lines displayed 




26B and 26C), along with a phenotypic switch from well-clustered toward a more spindle-
like mesenchymal morphology in 2D culture (Figure 26D). This confirms that TNFα 
activates the expression of cJUN and CCL2 and promotes a more aggressive BL 
phenotype. 
 
Figure 26. TNFα overexpression leads to induction of cJUN and CCL2. (A) Flow cytometric 
analysis of TNFα expression in CAPAN1-EV, CAPAN1-TNFα-OE, CAPAN2-EV, CAPAN2-TNFα-
OE cells. 561 nm laser was used to detect TNFα-mCherry expression. Count of gated cells is 
shown against fluorescence intensity, which correlates to TNFα expression. n=3. (B and C) 
Western blot analysis of cJUN and CCL2 in CAPAN1-TNFα-OE cells (B) as well as CAPAN2-
TNFα-OE cells (C). Actin was used as a loading control. Representative of three independent 
experiments. (D) Representative bright field images show morphology of CAPAN1-EV, CAPAN2-
EV and their corresponding TNFα overexpression cell lines. 
 
3.4.7 TNFα induces CCL2 expression via cJUN in PDAC  
To determine whether cJUN was essential for TNFα-induced CCL2 expression, we 
utilized TNFα-OE cell lines and subjected them to cJUN siRNA transfection to test 
whether CCL2 expression is altered. Indeed, cJUN and CCL2 levels were significantly 




cJUN, the induction of CCL2 was alleviated (Figure 27A and 27B). This data suggests 
that TNFα induces CCL2 expression through a cJUN-dependent mechanism.  
 
Figure 27. TNFα induced CCL2 is dependent on cJUN. (A and B) CAPAN1-TNFα-OE (A) and 
CAPAN2-TNFα-OE (B) cells were transfected with either siCtrl or sicJUN for 48 h. Cell lysates 
were subjected to Western blot analysis to test the expression of cJUN, CCL2. Actin was used as 
a loading control. Representative of three independent experiments. 
 
3.5 TNFα monotherapy does not improve overall survival  
So far, we identified a positive feed forward loop that TNFα+ producing macrophages 
induce cJUN-CCL2 signaling in tumor cells, further recruiting macrophages to sustain the 
BL subtype identity. Therefore, we investigated whether inhibition of TNFα alone was able 
to abrogate this feed forward loop and support a favorable prognosis. A syngeneic KPC 
mouse model was established by implanting KPCbl6 cells into C57BL/6J mice (Figure 
28A). After tumor development, mice were administered anti-TNFα antibodies or IgG 
isotype control via i.p. injection. Survival was recorded when mice reached end point 
criteria, for example 20 % bodyweight lost, unkempt hair, looking dull or abnormal posture. 






Figure 28. Inhibition of TNFα failed to improve the survival of syngeneic KPC mice. (A) 
illustration of experimental settings. 10-weeks old male C57BL/6J mice were orthotopically 
transplanted with 3.5 x 104 KPCbl6 cells. Tumor development was ensured by ultrasound. Anti-
mouse TNFα antibody (10 μg/g body weight) was applied three times per week. (B) Kaplan-Meier 
plot indicating survival of IgG (red) and anti-TNFα-treated (blue) syngeneic KPC mice. Median 
survival (ms) as well as significance (as per log-rank test) are indicated. 
 
H&E staining was performed in the IgG and TNFα-treated syngeneic KPC tumors. Tumor 
histology showed poor differentiation in general; however, we did observe any difference 
between control and treatment groups (Figure 29A). Histological quantification of well-
differentiated tumors confirmed that there was no difference in well differentiated area 
between IgG and TNFα-treated tumors (Figure 29B). Additionally, blocking TNFα did not 
reduce the recruitment of CD45+ cells (Figure 29C and 29D). These data suggest that 





Figure 29. Inhibition of TNFα did not alter tumor differentiation or infiltration of CD45+ cells. 
(A) Representative tile scan images of H&E staining in IgG and anti-TNFα-treated syngeneic KPC 
tumors. Scale bar: 200 µm. (B) Quantification of well differentiated tumor areas in (A). Scatter 
plots show well differentiated tumor area as percentage of total tumor area per animal, as well as 
means ± s.d. as bar graphs. Mann-Whitney test was used for statistical analysis. n=5 in IgG; n=5 
in anti-TNFα. (C) Representative images of IF staining for CD45 in (A). (D) Quantification of CD45+ 
cells in (C). Scatter plots show average values per animal of counts per field of view as well as 
means ± s.d. as bar graphs. Mann-Whitney test was used for statistical analysis. n=5 in IgG; n=4 
in anti-TNFα. 
 
3.6 BRD4 controls cJUN expression via enhancer regulation 
Since it is not feasible to block the cJUN-CCL2 signaling axis by TNFα inhibition, and 




a potential chromatin regulator which may control cJUN expression in the BL subtype. 
Thus, we utilized a publicly available ChIP-seq dataset in PDAC cells (Diaferia et al., 2016) 
and examined differential occupancy of the active transcription mark Histone 3 lysine 4 
trimethylation (H3K4me3) as well as H3K27ac between CLA and BL cell lines by the 
Enrichr tool (Chen et al., 2013; Kuleshov et al., 2016). Strikingly, we found not only cJUN 
binding regions to be significantly enriched (defined by H3K4me3 and H3K27ac), but also 
the bromodomain co-regulator BRD4 in the BL-specific active genomic regions (Figure 
30). 
 
Figure 30. Enrichment score of cJUN and BRD4. Publicly available ChIP-seq dataset (Diaferia 
et al., 2016) was reanalyzed by F. Wegwitz (Department of Gynecology and Obstetrics, UMG, 
Germany) for the differential occupancy of H3K27ac and H3K4me3 (>2 fold change) between the 
BL and CLA PDAC cells using the Enrichr tool (Chen et al., 2013; Kuleshov et al., 2016). 
 
To validate whether there was an association between cJUN and BRD4, we made use of 
a published dataset of BRD4 ChIP-seq in acute myeloid leukemia (AML) with DMSO and 
JQ1 treatment (Bhagwat et al., 2016). JQ1 is a small-molecule inhibitor for bromodomain 
and extra-terminal domain (BET) family with high affinity towards BRD4 (Filippakopoulos 
et al., 2010). This data revealed a significant occupancy of BRD4 on cJUN enhancer 
regions. ChIP-seq data of H3K27ac as well as enhancer marker Histone 3 lysine 4 
monomethylation (H3K4me1) also displayed a strong enrichment at cJUN enhancer loci 




performed individual ChIP-qPCR experiments for BRD4 to confirm binding over the 
putative enhancer regions of cJUN. Indeed, these three loci were found to be strongly 
occupied by BRD4. As predicted, BRD4 lost its occupancies on these sites following 8 h 
JQ1 treatment (Figure 31B).  
 
Figure 31. BRD4 occupies cJUN enhancer loci. (A) Coverage of BRD4 ChIP-seq in acute 
myeloid leukemia (AML) in vehicle control (VC; black) and JQ1-treated (blue) conditions (Bhagwat 
et al., 2016), as well as H3K27ac and H3K4me1 ChIP-seq in CLA cells (CAPAN2; blue) and BL 
cells (PANC1; black) (Diaferia et al., 2016) at the cJUN gene locus. (B) ChIP for BRD4 was 
performed in BL PANC1 cells upon DMSO and JQ1 treatment for 8 h followed by qRT-PCR 
analysis. Red dashed line indicates average IgG isotype control. Bar graphs show means ± s.d. 
Mann-Whitney test was used for statistical analysis. n=3. 
 
To validate the ChIP-qPCR results, which implies a regulation of cJUN by BRD4, we 
examined the expression of cJUN upon BRD4 depletion in BL cell lines. First, PANC1 




32A). Accordingly, siBRD4 #1 was chosen to perform further analysis. Next, BL cell lines 
were tested for cJUN expression upon BRD4 silencing. We observed a significant 
reduction of cJUN following BRD4 silencing in both PANC1 and MiPaCa2 cell lines 
(Figure 32B), suggesting that BRD4 regulates cJUN expression.  
 
Figure 32. BRD4 positively regulates cJUN in BL cells. (A) Western blot analysis for BRD4 in 
BL PANC1 cells transfected with either siCtrl or siRNAs targeting BRD4 for 48 h. (B) Western blot 
analysis of BRD4 and cJUN in siBRD4 or siCtrl transfected BL PANC1 and MiaPaCa2 cells. Actin 
was used as loading control. Representative of three independent experiments.  
 
3.7 Pharmacological inhibition of the BRD4-cJUN-CCL2 axis supports 
a favorable prognosis in preclinical mouse model 
To elucidate the potential of pharmacological inhibition of BRD4, BL PANC1 cells were 
subjected to JQ1 treatment at different concentrations. As expected from siBRD4 
experiments, JQ1 treatment led to a significant downregulation of cJUN at a concentration 






Figure 33. JQ1 treatment leads to reduction of cJUN. PANC1 cells were treated with JQ1 at 
indicated concentrations. After 24 h, cells were harvest and subjected for Western blot analysis 
for cJUN. Actin was used as loading control. Representative of three independent experiments. 
 
To investigate the therapeutic effect of JQ1 inhibition on the cJUN-CCL2 signaling axis in 
vivo, we established a syngeneic orthotopic KPC mouse model using tumor cells derived 
from KPC mice implanted in 10-week old male C57BL/6J mice (Figure 34A). Tumor 
growth was detected by sonography on day 10 post-transplantation. After tumor 
development, mice were treated with DMSO or JQ1 (50 mg/kg bodyweight) daily over 
three weeks. Survival data was recorded when mice reached end point criteria, as 
mentioned previously. Under DMSO control treatment, mice only survived for 18 days 
(median survival). However, JQ1 treatment significantly prolonged median survival to 29 





Figure 34. JQ1 resulted in a significant improvement of survival. (A) Diagram of experimental 
settings to investigate the therapeutic effect of JQ1 in vivo. 10-weeks old male C57BL/6J mice 
were orthotopically implanted with 3.5 x 104 KPC tumor cells derived from KPC mice. After 10 
days of transplantation, (B) Ultrasound was performed to detect tumor growth. Mice were 
administrated with JQ1 (50 mg/kg bodyweight) and DMSO control daily. (B) Kaplan-Meier plot 
indicating survival of DMSO (red) and JQ1-treated (blue) syngeneic KPC mice. Median survival 
(ms) as well as significance (as per log-rank test) are indicated. 
 
In order to evaluate the potential changes of tumor histology following JQ1 treatment, 
H&E staining was performed in the DMSO- and JQ1-treated syngeneic KPC tumors 
followed by whole tissue tile image scans (Figure 35A). Of note, PDAC tumors derived 
from syngeneic KPC mice exhibit BL/poorly differentiated histology. Notably, JQ1-treated 
tumors were observed to gain a more differentiated phenotype, which significantly 
recapitulates a CLA phenotypic state. The proportion of well differentiated tumor area was 





Figure 35. JQ1 treatment restrains tumor dedifferentiation. (A) Representative images of H&E 
staining in pancreatic tumor tissues derived from DMSO control and JQ1-treated syngeneic KPC 
model. I-III depict higher magnification images. Scale bar: representative images (top): 200 µm; 
higher magnification images (bottom): 10 µm. (B) Scatter plot showing quantification of well 
differentiated tumor area as percentage of the total tumor area in DMSO- and JQ1-treated mice, 
as well as means ± s.d. as bar graphs. n=8, DMSO; n=7, JQ1. Mann-Whitney test was used for 
statistical analysis. 
 
Since a phenotypic switch could be seen in the JQ1 treated tumor tissues, we investigated 
how tumor cells changed their cellular plasticity. Firstly, VIM expression was investigated 
by performing IF staining in the DMSO- and JQ1-treated tumors. A significant reduction 
of VIM with the application of JQ1 was observed (Figure 36A and 36B), which could 
partially explain the reduced poorly differentiated phenotype in the JQ1-treated tumors. 
To further validate whether the JQ1-triggered phenotypic switch was mediated through 
cJUN, the expression of TNFα and cJUN as well as CCL2 were probed in the syngeneic 
KPC tumors. It showed that cJUN was dramatically reduced in the treatment of JQ1 
(Figure 36A and 36C), concomitant with a reduction in the expression TNFα and CCL2 
(Figure 36A, 36D and 36E), resulting a reduction of the infiltration of CD45+ cells (Figure 
36A and 36F). Taken together, these data suggest that inhibition of BRD4 by JQ1 




the infiltration of TNFα+ immune cells in the TME, and thus, supports a favorable 
prognosis in PDAC.  
 
Figure 36. JQ1 alone reduces inflammatory immune microenvironment and EMT factors. 
(A) Representative images of IF staining for vimentin (VIM), cJUN, TNFα, CCL2, and CD45 in 
syngeneic KPC tumors with DMSO and JQ1 treatment. (B-E) Intensity quantification of VIM (B), 
cJUN (C), TNFα (D), and CCL2 (E). Scatter plots show values in arbitrary units (AU) as an 
average per animal, as well as means ± s.d. as bar graphs. n=5 in DMSO; n=5 in JQ1. Mann-
Whitney test was used for statistical analysis. (F) CD45+ cells of (A). Scatter plots show average 
count values per animal per F.o.V. as well as means ± s.d. as bar graphs. Mann-Whitney test was 







4.1 The role of TNFα in PDAC plasticity 
Tumor subtype-specific environmental factors play a major role in disease prognosis. In 
PDAC, the subtype-specific inflammatory immune signals determine distinct prognosis in 
patients. Recent transcriptional profiling studies in PDAC tumors identified a complex 
heterogeneity within stromal immune components (activated stroma vs. immune 
components) and tumor epithelium (CLA vs. BL) (Moffitt et al., 2015; Puleo et al., 2018). 
CLA subtype is correlated with better prognosis compared to BL subtype (Moffitt et al., 
2015). Nevertheless, how subtype-specific molecular events shape the inflammatory 
immune microenvironment, and hence determines PDAC prognosis remains unclear. 
As a key inflammatory cytokine, TNFα was originally identified to induce the necrosis of 
transplanted methylcholanthrene-induced sarcomas in mice (Carswell et al., 1975). 
However, subsequent evidence unveiled a paradoxical role of TNFα in tumor promotion 
(Calcinotto et al., 2012). In ovarian cancer, TNFα was able to promote tumor cell 
spreading to other organs by upregulating a range of cytokines (Kulbe et al., 2007). 
Besides, TNFα concentrations was higher in non-small-cell lung cancer patient serum 
sample; increased TNFα level was associated with high lymphoid and distant metastasis 
(Shang et al., 2017).  Similar findings were reported in PDAC, where TNFα levels were 
negatively correlated with PDAC patient survival, as revealed by TMA analysis. TNFα 
neutralization in combination with chemotherapeutics significantly improved mice survival 
(Zhao et al., 2016).  
Based on the notion that TNFα may play a role in promoting PDAC progression, we 
demonstrated the correlation between high-level TNFα and high-grade/poorly 
differentiated tumors of KPC mice and PDAC patient biopsies. Mouse orthotopic 
transplantation model using the CLA and BL cells also confirmed the profound enrichment 
of TNFα in the BL tumors. Thus, we show a phenotype-dependent expression of TNFα. 
Addtionally, studies in PDAC suggest a marked correlation of TNFα-related signatures to 




Chan-Seng-Yue et al., 2020). For instance, transcriptomic analysis of PDAC patient 
tumors revealed a significant enrichment of TNFα signaling pathway in the inflammatory 
stromal component corresponding to BL subtype (Puleo et al., 2018). Additionally, studies 
from Chan-Seng-Yue et al. and Miyabayashi et al. noted that TNFα-signaling pathway 
was significantly enriched in the BL tumors and invasive PDAC phenotypes (Miyabayashi 
et al., 2020; Chan-Seng-Yue et al., 2020). However, whether PDAC subtype-specific 
TNFα expression restrain or promote disease aggressiveness remains to be established. 
We show that exogenous TNFα administration switched W/M differentiated tumors into 
poorly differentiated BL phenotypic state of a CLA-derived orthotopic mouse model. This 
phenotypic change was further validated with IF staining for the BL-specific marker 
KRT81 (Noll et al., 2016; Muckenhuber et al., 2018), which is highly expressed in the 
TNFα-treated CLA orthotopic tumors, highlighting the significant role of TNFα in tumor-
promoting and subtype-switching in PDAC. Besides tumor subtype switch, we also 
observed that TNFα-induced BL phenotypic state was associated with an increased 
infiltration of CD45+ immune cells.  
TNFα was found to induce the invasive capacity of the CLA cells, concomitant with 
reduction of a low-grade specific TF KLF5 and induction of EMT inducer ZEB1. ZEB1 is 
a vital TF known to enhance the invasive and metastatic capacity of PDAC (Krebs et al., 
2017). Tumor cells lacking ZEB1 switched from mesenchymal to an epithelial phenotype 
in PDAC (Wellner et al., 2009). On the other hand, KLF5 was shown to be specifically 
expressed in the CLA cells as well as low-grade tumors in PDAC (Diaferia et al., 2016). 
KLF5 plays an essential role in the maintenance of the CLA phenotype via regulating a 
subset of epithelial gene signatures (Diaferia et al., 2016). There are lineage genes and 
TFs, which are important for the maintenance of subtype identity (Neph et al., 2012). 
Studies have uncovered an association of ELF3, HNF1B, and GATA6 with low-grade 
tumors, and they are characterized as CLA lineage markers (Collisson et al., 2011; 
Diaferia et al., 2016; Martinelli et al., 2017; Somerville et al., 2018). However, TP63, GLI2 
are required for the BL subtype identity (Adams et al., 2019; Somerville et al., 2018). 
Together, for the first time, we show that TNFα can switch the phenotypic identity by 




Hallmarks of EMT and inflammatory response were significantly enriched in the TNFα-
treated CLA cells revealed by RNA-seq analysis, in line with our previous observations of 
TNFα induced BL phenotype in vivo and in vitro. ‘KRAS signaling down’ and ‘myogenesis’ 
pathways induced by TNFα also appeared in the aggressive PDAC phenotypes 
evidenced by Miyabayashi et al. (Miyabayashi et al., 2020). Additionally, we show that 
TNFα caused downregulation of majority of the CLA gene signatures including ELF3, 
FOXQ1, CEACAM6, CEACAM5, as well as AGR2, and upregulation of BL markers such 
as KRT5, KRT14, and EGFR. Taken together, TNFα was firstly evidenced to induce CLA 
to inflammatory BL phenotypic switch and favors tumor progression via regulation of 
epithelial plasticity in PDAC (Figure 37).  
 
Figure 37. Illustration of TNFα induced CLA to BL subtype switch. CLA PDAC subtype 
displays well-differentiated tumor phenotype with limited expression of TNFα and CD45+ cells. 
Conversely, BL subtype has abundant TNFα in tumor tissues. Exogenous TNFα leads to subtype 
switch from CLA to BL phenotypic state via downregulation of CLA-associated transcriptional 





4.2 PDAC subtype-dependent stromal microenvironment  
Based on the observations of subtype-dependent expression of TNFα in tumor tissues, 
the initial hypothesis was that TNFα was produced by BL tumor cells. However 
surprisingly, contrary to Zho et al. who reported the source of TNFα expression from the 
PDAC cell lines (i.e. PANC1 and MiaPaCa2 cell lines) (Zhao et al., 2016), we found that 
none of the PDAC cells including CAPAN1, CAPAN2, PANC1, and MiaPaC2 express 
TNFα. Though different antibodies were used for flow cytometry analysis, cell lines might 
differ in the aspects of source and passages. We further validated that these cells do not 
produce soluble TNFα via ELISA, suggesting that PDAC cells are not the source of TNFα 
in the BL tumors. 
Except for the epithelial cells in the TME, stromal immune counterpart is equally important 
for modulating subtype identity (Ho et al., 2020). We speculated that TNFα might come 
from the inflammatory microenvironment of the BL subtype. Examination of human- and 
murine-specific TNFα revealed that only murine TNFα was detected in the BL orthotopic 
transplanted mice with no trace of human TNFα, indicating the source of TNFα being host 
inflammatory microenvironment. In the BL tumors, CD45+ and CD68+ cells were highly 
infiltrated relative to the CLA tumors. Recently, single-cell analysis in PDAC mouse 
models unveiled that macrophage was the most predominant cell population in the late 
stage of the disease (Hosein et al., 2019). Thus, it is highly likely that TNFα-producing 
CD68+ macrophages present in PDAC in a subtype-dependent manner. 
In the TME, CCL2 is a chemotactic cytokine known to recruits macrophages through 
CCL2-CCR2 signaling (Nagarsheth et al., 2017). Mounting evidence have reported that 
CCL2 signaling-mediated macrophages contribute to tumor progression and metastasis 
in multiple cancers (Chen et al., 2018; Fader et al., 2010; Qian et al., 2011; Zhang et al., 
2010). To take an example of breast cancer, CCL2 was reported to recruit macrophages 
to facilitate tumor cell metastasize to the lung (Qian et al., 2011). However, after blockage 
of CCL2 by anti-CCL2 antibody, infiltrated macrophages were dramatically reduced, as 
well as lung metastases. Consequently, mice survival was significantly prolonged (Qian 




cancer, ovarian cancer, as well as breast cancer (Li et al., 2018; Ueno et al., 2000). In 
our study, levels of several cytokines including CCL2 were extremely high in the BL cells 
analyzed by RNA-seq data obtained from publicly available dataset (Bailey et al., 2016). 
High-level CCL2 in the BL cells was further validated by human cytokine profiler kit. 
Furthermore, a strong association of CCL2 with the squamous (i.e. BL) PDAC subtype 
(Puleo et al., 2018) could be seen. Thus, we show that different PDAC subtype links to 
distinct TME. Compared to CLA, BL subtype has an inflammatory TME with high 
expression of CCL2 and infiltration of TNFα-producing CD68+ macrophages. 
Similarly, the work from Li et al. highlighted that tumor intrinsic cytokine determines the 
immune heterogeneity of PDAC (Li et al., 2018). They identified CXCL1 as a pivotal 
intrinsic factor that changes the subtype identity from T cell-low to T cell-high tumors. 
Besides, inhibition of colony stimulating factor 1 receptor (CSF1R) was able to alter the 
composition of TME (Candido et al., 2018). Ligand CSF1 mediated signaling is important 
for the differentiation and maintenance of macrophage (Sehgal et al., 2018). Targeting of 
CSF1R led to significantly reduction of macrophages in tumor tissues. Therefore, tumor 
switched from BL to CLA phenotype and mice survived longer (Candido et al., 2018), 
suggesting the significant role of macrophage in subtype identity.  
4.3 The role of JUN/AP1 family in tumor plasticity   
AP1 transcription factor has been extensively studied of its function regarding the 
regulation of inflammatory response (Lopez-Bergami et al., 2010). However, the 
implication of AP1 family TF complexes in PDAC aggressiveness remains elusive. AP1 
TF complexes consist of JUN (cJUN, JUNB, JUND), Fos (c-FOs, FOSB, FRA1, FRA2), 
activating transcription factor (ATF) (ATF2, ATF3, B-ATF, JDP1, JDP2), as well as 
musculoaponeurotic fibrosarcoma (MAF) (c-Maf, MafB, MafA, MafG/F/K and Nrl) 
(Shaulian and Karin, 2002). They form either homo- or heterodimeric protein complexes 
(e.g. cJUN-cJUN, cJUN-FOS) for enhancing DNA binding to regulate their gene targets 
(Eckert et al., 2013). In recent years, emerging studies unveiled the potential role of AP1 





We identified that JUN/AP1 pathway was significantly associated with the PDAC subtype 
identity. cJUN/AP1 and JUNB/AP1 were mutually exclusively expressed in the PDAC 
subtype specific manner. Our in vitro and in vivo findings suggest that cJUN is mainly 
involved in the maintenance of BL-inflammatory program, whereas JUNB is exclusively 
expressed in the CLA tumors.  In line with our findings, Diaferia et al. have identified high 
expression of JUNB in low-grade tumors based on immunochemistry staining (Diaferia et 
al., 2016), confirming the correlation of JUNB with the CLA subtype. Although, a recent 
study has shown that cJUN/AP1 induces inflammatory program in chronic pancreatitis 
(Cobo et al., 2018), the transcriptional activation of cJUN in PDAC subtype specificity 
remains unresolved.  
By intersecting JUNB or cJUN targets with CLA-related or BL-related ATAC-peaks 
respectively, we find that ‘cell-cell adhesion regulation’ and ‘epithelial cell differentiation’ 
gene sets were enriched in JUNB/CLA-related regions, which support our findings that 
JUNB restricted to well-differentiated tumors. On the other hand, pathways of ‘response 
to growth factor’, ‘leukocyte migration’, as well as ‘regulation of cytokine production’ were 
enriched in cJUN/BL-related regions, suggesting the role of cJUN in immune regulation. 
Consistently, we detected strong occupancy of JUNB on CDH1 at promoter and enhancer 
sites, associated with H3K27ac occupancy. CDH1 encodes for ECAD, which is a 
transmembrane protein, involved in the formation of adherens junctions to mediate cell to 
cell connections (van Roy and Berx, 2008). ECAD is typically expressed in the epithelial 
cells, playing an essential role in the maintenance of epithelial structure (Natalwala et al., 
2008). In the BL cells, we show that cJUN occupies both promoter and enhancer loci of 
VIM. VIM is a family member of intermediate filaments, maintaining mesenchymal 
features (Ivaska et al., 2007). These findings support the idea that JUNB might involve in 
maintenance of epithelial differentiation in the CLA subtype, while cJUN is, in fact, 
required for the tumor dedifferentiation in the BL subtype.  
Together, we show that cJUN and JUNB exert distinct functions in PDAC subtype 
maintenance. We proposed a model to elaborate cJUN- and JUNB- mediated PDAC 






Figure 38. JUNB and cJUN in controlling PDAC subtype identity. JUNB is selectively 
expressed in the CLA PDAC subtype and maintain the epithelial differentiation. cJUN is restricted 
to the BL PDAC subtype which is highly infiltrated with CD68+ cells. The possibility of other lineage 
transcription factors cooperative with JUNB or cJUN still needs to be tested. 
 
4.4 cJUN-regulatory network in macrophages recruitment and therapy 
resistance   
We show that cJUN-OE cells displayed an invasive phenotype in CLA PDAC cells. Our 
findings align with the previous report where cJUN overexpression showed similar 
phenotype in MCF-7 breast cancer cells (Smith et al., 1999). Notably, MCF7 cell line 
identified as luminal A subtype (Adelaide et al., 2007), which displays identical phenotype 
to the PDAC low-grade/CLA subtype (Adelaide et al., 2007). Consistently, another finding 
in breast cancer model showed that loss of cJUN activity associated with reduced tumor 
cell migration and invasive behavior (Jiao et al., 2010). Thus, cJUN promotes the shift of 
CLA tumors into more invasive BL phenotypic state. Moreover, BL tumor aggressiveness 
is often associated with increased chemoresistance profile in PDAC (Aung et al., 2018). 
Since cJUN-OE switched cells towards a more BL phenotype, we proposed that cJUN-




tumors respond efficiently to chemotherapy, in particular with m-FOLFIRINOX and nap-
paclitaxel/gemcitabine (Aung et al., 2018).  We compared IC50 of oxaliplatin, SN38 (an 
activate metabolite of irinotecan) that are the active components of FLOFIRINOX, as well 
as gemcitabine in cJUN-OE cells. Oxaliplatin was designed based on platinum, forming 
DNA-platinum adducts to inhibit DNA replication and induce cell apoptosis (Zoetemelk et 
al., 2020). While irinotecan is a topoisomerase inhibitor and it slightly inhibits DNA 
synthesis (Zoetemelk et al., 2020). However, the effect was much more augmented when 
it is transformed into an activated metabolite SN38. SN38 accelerates DNA damage via 
generating chromosome aberrations and ultimately leads to apoptosis (Zoetemelk et al., 
2020). cJUN-OE cells showed more resistance to these drugs compared to EV cells. 
Similarly, Lipner et al. reported that cJUN is essential for conferring resistance to FOLFOX 
(combination of 5-FU and oxaliplatin) treatment in PDAC mouse models (Lipner et al., 
2020). Furthermore, lentiviral-mediated cJUN depletion significantly increased the 
sensitivity of PDAC cells to FOLFOX (Lipner et al., 2020), confirming the crucial role of 
cJUN in chemoresistance, thereby maintaining BL phenotypic state. 
Besides cJUN functions in the neoplastic-epithelial plasticity, we also identified its crucial 
role in the recruitment of inflammatory immune cells. We hypothesized that cJUN might 
transcriptionally regulate CCL2 for the recruitment of TNFα-producing macrophages in 
the BL tumors. Our novel findings show that cJUN directly controls CCL2 expression via 
enhancer-promoter regulation in BL PDAC cells. Importantly, cJUN-mediated CCL2 
expressions is found in the established PDAC cells as well as cJUN-high cell lines isolated 
from patient-derived xenograft (PDX). Together, these findings suggest that cJUN 
positively regulates CCL2 for the maintenance of TNFα-mediated inflammatory program 
in the BL PDAC subtype. Of note, we showed that high expressions of TNFα is linked to 
inflammatory and poorly differentiated/BL phenotypic state.   
Interestingly, our results show that TNFα induces cJUN-CCL2 feed-forward loop in CLA 
PDAC subtype. Constitutive expression of TNFα in the CLA cells led to a highly 
invasive/BL phenotypic identity, which is functionally similar to the cJUN-OE CLA PDAC 
cell lines.  Importantly, loss of cJUN significantly suppressed the TNFα induced CCL2, 




we identified a cJUN-driven inflammatory BL program, which is essential for maintenance 
of TNFα-mediated PDAC aggressiveness (Figure 39).  
 
 
Figure 39. Illustration model of cJUN-CCL2-TNFα positive feedforward loop. cJUN activates 
CCL2 to recruit CD68+ macrophages which secrete TNFα, and in turn, fostering tumor cells and 
activating cJUN-CCL2 signaling axis to promote a worse phenotype. 
 
4.5 Monotherapy of anti-TNFα is not ideal for PDAC 
Anti-TNFα monotherapy has been approved in clinical use for many types of chronic 
inflammatory disease including rheumatoid arthritis, Crohn’s disease, psoriatic arthritis, 
ankylosing spondylitis, ulcerative colitis, as well as severe psoriasis (Feldmann, 2002; 
Jackson, 2007; Thalayasingam and Isaacs, 2011). To date, there are five distinct 
monoclonal antibodies available for targeting TNFα: etanercept, infliximab, adalimumab, 
golimumab, and certolizumab (Thalayasingam and Isaacs, 2011). Despite the promising 
effect of anti-TNFα conferred in the inflammatory disease, whether it is effective for cancer 




In our study, anti-TNFα treatment did not improve the overall survival of syngeneic KPC 
mice, which is a highly aggressive immunocompetent mouse model.   We anticipated that 
TNFα monotherapy might switch the BL tumors into more favorable CLA-like phenotype. 
However, neither tumor differentiation nor recruitment of inflammatory immune cells 
(CD45+ and CD68+) were altered following TNFα monotherapy. There could be two major 
reasons for the failure of anti-TNFα monotherapy: (i) tumors developed from syngeneic 
KPC mice are highly heterogeneous and surrounded by dense stroma tissues including 
fibroblasts, extracellular matrix, and vasculature (Neesse et al., 2011; Ying et al., 2016). 
Desmoplastic reaction makes it difficult for TNFα neutralizing antibodies to penetrate and 
reach PDAC tumors. Similarly, CCL2 neutralizing antibody alone did not improve the 
survival of PDAC mouse model (Kalbasi et al., 2017); (ii) KPC-derived tumors display 
extremely aggressive phenotype, which constitutively expresses cJUN-mediated CCL2-
TNFα axis. Therefore, targeting TNFα alone is not sufficient to prevent the overall tumor 
progression. Therefore, targeting cJUN alone or in combination with TNFα monotherapy 
may improve the outcome of BL tumors.   
4.6 Preclinical inhibition of BRD4 confers favorable prognosis of BL 
tumors  
Considering that anti-TNFα therapy failed to improve the prognosis in PDAC, and there 
was no pharmacological inhibitor available to specifically target cJUN, we assumed that 
a potential chromatin regulator could be serve as a candidate for the blocking cJUN-
mediated signaling axis. Interestingly, our data showed that chromatin regulator BRD4 
was highly enriched in the BL subtype (Diaferia et al., 2016). BRD4 belongs to 
bromodomain and extraterminal domain (BET) family, it is a chromatin remodeler that 
functions as a chromatin ‘reader’ to recognizes the acetylated histones and regulate gene 
expression (Belkina and Denis, 2012; Wu et al., 2013). Study has shown that BRD4 was 
highly expressed in the late stage of PDAC mouse tumors (Hosein et al., 2019). Most 
recently, the work from Shu et al. revealed that in breast cancer patients, BRD4 was 
significantly higher expressed in the basal (likely to BL PDAC) tumors compared to 




This enrichment analysis gave us an indication that there might be a regulation between 
BRD4 and cJUN. And if so, BRD4 could be exploit as a therapeutic target for inhibiting 
cJUN. JQ1 is a small molecular inhibitor, which competitively binds to the pocket of the 
bromodomain and replaces the BRD4 protein from acetylated histones (Filippakopoulos 
et al., 2010). By reanalyzing public ChIP-seq data in acute myeloid leukemia (AML) cells 
(Bhagwat et al., 2016), we showed that JQ1 led to decreased BRD4 occupancy at 
enhancer regions of cJUN. Consistently, JQ1 resulted in reduced occupancy of BRD4 at 
cJUN enhancer sites in PDAC, as validated by ChIP-qPCR. The positive regulation of 
BRD4 on cJUN was confirmed by reduced expression of cJUN upon abrogation of BRD4 
by siRNA. As expected, BET inhibitor JQ1 led to reduction of cJUN in the BL cells.  
Mazur et al. showed that JQ1 resulted in reduced expression of CD45+ cells as well as 
F4/80+ macrophages. The JQ1 therapy alone, or in combination with histone deacetylase 
(HDAC) inhibitor, significantly improved the survival of PDAC mouse model (Mazur et al., 
2015, Andricovich et al., 2018). Thus, pharmacological inhibition of BRD4 via JQ1 
significantly improve the pre-clinical outcome of PDAC. Importantly, we show that JQ1 
monotherapy switched the highly aggressive/BL tumors into more CLA-like phenotypic 
state, which was not feasible with anti-TNFα monotherapy. We provide a very strong 
evidence that pharmacological inhibition of BRD4 via JQ1 significantly disrupted cJUN-
mediated BL inflammatory program.  Together, our findings suggest that JQ1 therapy 





Figure 40. Schematic illustration of JQ1 mediated favorable prognosis in PDAC. cJUN could 
be targeted by inhibiting of BRD4 with BET inhibitor JQ1, thus, leading to well differentiated 
phenotype and less infiltrates for favoring a better prognosis. 
 
4.7 Concluding remarks  
Complex tumor stroma heterogeneity and cancer cell plasticity are the major challenges 
in PDAC poor prognosis and therapy resistance. Recent molecular subtyping of PDAC 
has significantly improved the molecular understanding of this lethal disease. Studies 
have shown that lineage-specific TFs and their associated gene signatures tightly control 
PDAC subtype identity and disease aggressiveness. In addition, the tumor subtype 
identity can be shaped by external stimuli from the existing tumor immune 
microenvironment. However, the precise mechanism of how this regulatory program 
operates is still largely unknown.  
We provide a set of compelling evidence that explains how neoplastic-specific 
transcriptional reprograming modulates intra-tumor immune heterogeneity, which 




can indeed modulate these epigenetic-driven transcriptional networking and allow us to 
induce a favorable subtype switch.       
 Collectively, we report that: 
 
➢ High expression of TNFα is restricted to the high-grade/poorly differentiated BL 
subtype, whereas CLA subtype is low-grade/well-to-moderately differentiated with 
low-proinflammatory immune infiltrations;   
 
➢ Two antithetical and mutually exclusive AP1-driven transcriptional programs 
determine subtype identity and, thus, prognosis. JUNB/AP1 controls CLA tumor 
identity, whereas cJUN/AP1 controls the BL phenotype; 
 
➢ BL-restricted cJUN maintains a pro-inflammatory gene expression program by 
controlling chromatin accessibility and enhancer potentiation; it thus recruits 
TNFα+ macrophages in the microenvironment via CCL2 to sustain an inflammatory 
niche; 
 
➢ CLA-restricted JUNB cannot support this pro-inflammatory identity and precludes 
macrophages recruitment; however, TNFα treatment suffices for switching CLA-
tumors towards the aggressive BL identity;  
 
➢ BRD4-bound enhancers support the cJUN-CCL2-TNFα axis, and hence, 
macrophages recruitment. Treatment with a known BET inhibitor disrupts this axis 
and allows reprogramming of poorly differentiated/BL-tumors into more 
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